var title_f18_9_18576="Hypomelanosis of Ito - trunk and arms";
var content_f18_9_18576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypomelanosis of Ito",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple hypopigmented patches that follow the lines of Blaschko are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18576=[""].join("\n");
var outline_f18_9_18576=null;
var title_f18_9_18577="Lifting exercise PI";
var content_f18_9_18577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Lifting exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bend your elbows to 90 degrees. Place the rubber band near the elbows and lift your arms four or five inches away from the body, holding for five seconds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18577=[""].join("\n");
var outline_f18_9_18577=null;
var title_f18_9_18578="Patient information: Low testosterone in men (The Basics)";
var content_f18_9_18578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/88640\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?26/34/27180\">",
"         Androgen replacement medicines (testosterone)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/45/36562\">",
"         Patient information: Androgen replacement in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/46/29409\">",
"         Patient information: Androgens and other hormones to boost sports performance: Risks and side effects (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/24/386\">",
"         Patient information: Sex problems in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/30/44513\">",
"         Patient information: When men develop breasts (gynecomastia) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/47/41713\">",
"         Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/33/29205\">",
"         Patient information: Sexual problems in men (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Low testosterone in men (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H30064700\">",
"      <span class=\"h1\">",
"       What is testosterone?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Testosterone is 1 of a few different &ldquo;male hormones&rdquo; or what doctors call &ldquo;androgens.&rdquo; Testosterone is the most important androgen that men make. It helps with muscle strength, sex drive, and bone strength.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30064715\">",
"      <span class=\"h1\">",
"       What is low testosterone in men?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Low testosterone is when the body makes too little testosterone. The medical term for this is &ldquo;androgen deficiency,&rdquo; but many people call it just &ldquo;low T.&rdquo; As men get older, it is normal for levels of testosterone to get a bit lower. But when the levels of testosterone get",
"      <strong>",
"       too",
"      </strong>",
"      low, men can have symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30064730\">",
"      <span class=\"h1\">",
"       What are the symptoms of low T?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms are different depending on how long a man has had low T.",
"     </p>",
"     <p>",
"      At first, men with low T:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel tired, especially at the end of the day",
"       </li>",
"       <li>",
"        Have little or no interest in sex (also called &ldquo;low libido&rdquo;)",
"       </li>",
"       <li>",
"        Feel sad, down, or depressed",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After a year or more of having low T, men develop other symptoms or medical problems, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Loss of muscle",
"       </li>",
"       <li>",
"        Bone thinning",
"       </li>",
"       <li>",
"        Loss of facial or body hair",
"       </li>",
"       <li>",
"        Growing breasts (also called &ldquo;gynecomastia&rdquo;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30064745\">",
"      <span class=\"h1\">",
"       What causes low T in men?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Low T in men can be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Normal aging",
"       </li>",
"       <li>",
"        Injury or infection affecting the testicles (which make most of the testosterone in men)",
"       </li>",
"       <li>",
"        Certain treatments for cancer, including radiation, chemotherapy, and hormone therapy for prostate cancer",
"       </li>",
"       <li>",
"        Disorders that affect the pituitary gland, a gland at the base of the brain that controls all hormone-producing organs &nbsp;",
"       </li>",
"       <li>",
"        Other medical problems, such as liver and kidney disease, obesity, diabetes, and AIDS",
"       </li>",
"       <li>",
"        Other rare genetic problems",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30064760\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, if you have symptoms of low T, see your doctor or nurse. There are many things that can cause those symptoms. Your doctor or nurse can try to find out what might be causing them. A blood test can show whether you have low T, but you might not need that test if something else is causing your symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30064775\">",
"      <span class=\"h1\">",
"       How is low testosterone in men treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Low testosterone can be treated with testosterone replacement, which comes in shots, patches, gels, and tablets you put on your gums (",
"      <a class=\"graphic graphic_table graphicRef86166 \" href=\"UTD.htm?26/34/27180\">",
"       table 1",
"      </a>",
"      ). But low testosterone is not always treated, especially in men older than 60. That&rsquo;s because it&rsquo;s normal for testosterone to drop in men as they age. In fact, normal aging causes some of the same changes that happen in men with low testosterone, such as less energy or interest in sex.",
"     </p>",
"     <p>",
"      Men older than 60 might have androgen replacement if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        More than 1 blood test shows very low testosterone",
"       </li>",
"       <li>",
"        They have symptoms of low testosterone that bother them",
"       </li>",
"       <li>",
"        The symptoms are not caused by another disease or condition that doctors can treat",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Older men who have androgen replacement need regular screening tests for prostate cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30064807\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36562?source=see_link\">",
"       Patient information: Androgen replacement in men (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/46/29409?source=see_link\">",
"       Patient information: Androgens and other hormones to boost sports performance: Risks and side effects (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=see_link\">",
"       Patient information: Sex problems in men (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/30/44513?source=see_link\">",
"       Patient information: When men develop breasts (gynecomastia) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/47/41713?source=see_link\">",
"       Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"       Patient information: Sexual problems in men (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/9/18578?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 88640 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.25.216.6-E05BAE8337-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18578=[""].join("\n");
var outline_f18_9_18578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30064700\">",
"      What is testosterone?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30064715\">",
"      What is low testosterone in men?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30064730\">",
"      What are the symptoms of low T?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30064745\">",
"      What causes low T in men?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30064760\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30064775\">",
"      How is low testosterone in men treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30064807\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/88640\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/34/27180\">",
"      Androgen replacement medicines (testosterone)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36562?source=related_link\">",
"      Patient information: Androgen replacement in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/46/29409?source=related_link\">",
"      Patient information: Androgens and other hormones to boost sports performance: Risks and side effects (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/47/41713?source=related_link\">",
"      Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=related_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/30/44513?source=related_link\">",
"      Patient information: When men develop breasts (gynecomastia) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_9_18579="Serum sickness-like reaction";
var content_f18_9_18579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Serum sickness-like reaction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular erythematous plaques are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18579=[""].join("\n");
var outline_f18_9_18579=null;
var title_f18_9_18580="Morphologic features ARVD";
var content_f18_9_18580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Morphologic features in ARVD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 191px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Morphologic features in a 25-year-old man who died suddenly from arrythmogenic right ventricular dysplasia (ARVD). Panel A:Four chamber view cut of the heart specimen showing the transmural fatty replacement of the right ventricular free wall and the translucent infundibulum. Panel B: Panoramic histologic view of the same heart confirming that the replacement of the myocardium by fat is largely confined to the right ventricle (arrow) and substantially spares the interventricular septum as well as the left ventricular free wall (trichrome Heidenhain x 3).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Basso, C, Corrado, D, Rossi, L, et al. Morbid anatomy. In: Arrhythmogenic right ventricular cardiomyopathy - dysplasia, Nava, A, Rossi, L, Thiene, G (Eds), Elsevier, Amsterdam 1997. p.71-86, Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18580=[""].join("\n");
var outline_f18_9_18580=null;
var title_f18_9_18581="Inflammatory cells displacing myofibers in IBM";
var content_f18_9_18581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Inflammatory cells displacing myofibers in IBM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory cells invading necrotic myofibers and displacing other myofibers in inclusion body myositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven A Greenberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18581=[""].join("\n");
var outline_f18_9_18581=null;
var title_f18_9_18582="Nilotinib: Patient drug information";
var content_f18_9_18582=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nilotinib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     see \"Nilotinib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5501066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tasigna&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6860243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tasigna&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       An unsafe fast heartbeat may happen. Tell your doctor if you have a history of fast heartbeats, low potassium or magnesium levels. Your heartbeat will be watched with an ECG.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692098",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat stomach cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nilotinib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Long QT syndrome, low magnesium levels, or low potassium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701033",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to lactose, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698594",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will watch your heartbeat with a test called an ECG.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697233",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an irritated pancreas, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had recent stomach surgery or any stomach problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count. This drug may need to be stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698113",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change or loss of eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3014979",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Capsule may be opened and contents sprinkled on 1 teaspoon of applesauce. Swallow right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11991 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18582=[""].join("\n");
var outline_f18_9_18582=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501066\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6860243\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030039\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030041\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030040\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030045\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030046\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030048\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030043\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030044\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030049\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030050\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=related_link\">",
"      Nilotinib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_9_18583="Streptomycin: Drug information";
var content_f18_9_18583=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Streptomycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/48/40707?source=see_link\">",
"    see \"Streptomycin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/18/26917?source=see_link\">",
"    see \"Streptomycin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14595275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Streptomycin for Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F223222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Aminoglycoside;",
"     </li>",
"     <li>",
"      Antitubercular Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F223206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     For I.M. administration; I.V. use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     I.M.: 15-30 mg/kg/day or 1-2 g daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Brucellosis:",
"     </b>",
"     I.M.: 1 g daily in 2-4 divided doses for 14-21 days (with doxycycline) (Skalsky, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endocarditis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Enterococcal:",
"     </i>",
"     I.M.: 1 g every 12 hours for 2 weeks, 500 mg every 12 hours for 4 weeks in combination with penicillin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Streptococcal:",
"     </i>",
"     I.M.: 1 g every 12 hours for 1 week, 500 mg every 12 hours for 1 week in combination with penicillin.",
"     <b>",
"      Note:",
"     </b>",
"     For patients &gt;60 years, 500 mg every 12 hours for 2 weeks is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"     </b>",
"     <b>",
"      complex:",
"     </b>",
"     I.M.: Adjunct therapy (with macrolide, rifamycin, and ethambutol): 8-25 mg/kg 2-3 times weekly for first 2-3 months for severe disease (maximum single dose for age &gt;50 years: 500 mg) (Griffith, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Mycobacterium kansasii",
"      </i>",
"     </b>",
"     <b>",
"      disease (rifampin-resistant):",
"     </b>",
"     I.M.: 750 mg to 1 g daily  (as part of a three-drug regimen based on susceptibilities) (Campbell, 2000; Griffith, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Mycobacterium ulcerans",
"      </i>",
"     </b>",
"     <b>",
"      (Buruli ulcers):",
"     </b>",
"     I.M.: 15 mg/kg once daily for 8 weeks (WHO, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Plague:",
"     </b>",
"     I.M.: 30 mg/kg/day (or 2 g) divided every 12 hours until the patient is afebrile for at least 3 days.",
"     <b>",
"      Note:",
"     </b>",
"     Full course is considered 10 days (WHO, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tuberculosis:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Daily therapy:",
"     </i>",
"     15 mg/kg/day (maximum: 1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Directly observed therapy (DOT), twice weekly:",
"     </i>",
"     25-30 mg/kg (maximum: 1.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Directly observed therapy (DOT), 3 times weekly:",
"     </i>",
"     25-30 mg/kg (maximum: 1.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tularemia:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"     1-2 g  daily in divided doses every 12 hours (maximum: 2 g daily) for 7-14 days until the patients is afebrile for 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternative regimen:",
"     </i>",
"     2 g daily in 2 divided doses (maximum: 2 g daily) for 10 days (WHO, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F223217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/18/26917?source=see_link\">",
"      see \"Streptomycin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     For I.M. administration; I.V. use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     I.M.: 20-40 mg/kg/day (maximum: 1 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Mycobacterium ulcerans",
"      </i>",
"     </b>",
"     <b>",
"      (Buruli ulcers):",
"     </b>",
"     I.M.: 15 mg/kg once daily (maximum: 1 g) for 8 weeks (WHO, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Plague:",
"     </b>",
"     I.M.: 30 mg/kg/day divided every 12 hours for 10 days (WHO, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tularemia:",
"     </b>",
"     I.M.: 15 mg/kg twice daily (maximum: 2 g) for 10 days (WHO, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tuberculosis:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Daily therapy:",
"     </i>",
"     20-40 mg/kg/day (maximum: 1 g daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Directly observed therapy (DOT), twice weekly:",
"     </i>",
"     25-30 mg/kg (maximum: 1.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Directly observed therapy (DOT), 3 times weekly:",
"     </i>",
"     25-30 mg/kg (maximum: 1.5 g)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F223207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.: Manufacturer states dose reductions are necessary in patients &gt;60 years.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F223208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     The following adjustments have been recommended (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 24-72 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 72-96 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD): One-half the dose administered after hemodialysis on dialysis days.",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times weekly complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Administration via PD fluid: 20-40 mg/L (20-40 mcg/mL) of PD fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer every 24-72 hours; monitor levels (Aronoff, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F223189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inject deep I.M. into large muscle mass; midlateral thigh muscle (preferred site for children); midlateral thigh muscle or upper buttocks (adults);  alternate injection site areas. I.V. administration is not recommended; has been administered intravenously over 30-60 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F223228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Esmolol.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F223188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Part of combination therapy of active tuberculosis; used in combination with other agents for treatment of bacteremia caused by susceptible gram-negative bacilli, brucellosis, chancroid granuloma inguinale,",
"     <i>",
"      H. influenzae",
"     </i>",
"     (respiratory, endocardial, meningeal infections),",
"     <i>",
"      K. pneumoniae",
"     </i>",
"     , plague, streptococcal or enterococcal endocarditis, tularemia, urinary tract infections (caused by",
"     <i>",
"      A. aerogenes, E. coli, E. faecalis, K. pneumoniae, Proteus",
"     </i>",
"     spp)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14595276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Buruli ulcer (",
"     <i>",
"      Mycobacterium ulcerans",
"     </i>",
"     ), M&eacute;ni&egrave;re&rsquo;s disease,",
"     <i>",
"      Mycobacterium kansasii",
"     </i>",
"     infection;",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex (MAC)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F223230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Streptomycin may be confused with streptozocin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F223220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drug fever, headache, neurotoxicity, paresthesia of face",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, exfoliative dermatitis, skin rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ototoxicity (auditory), ototoxicity (vestibular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Azotemia, nephrotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Difficulty in breathing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing, and/or case reports: Drug reaction with eosinophilia and systemic symptoms (DRESS), toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F223192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to streptomycin, other aminoglycosides, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F223172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular blockade and respiratory paralysis:",
"     <b>",
"      [U.S. Boxed Warning]: May cause neuromuscular blockade and respiratory paralysis;",
"     </b>",
"     especially when given soon after anesthesia or muscle relaxants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause neurotoxicity;",
"     </b>",
"     usual risk factors include pre-existing renal impairment, concomitant neuro-/nephrotoxic medications. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage. Baseline and periodic caloric stimulation and audiometric tests are recommended with prolonged therapy. Discontinue treatment if signs of ototoxicity occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hearing impairment: Use with caution in patients with pre-existing vertigo, tinnitus, or hearing loss.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment:",
"     <b>",
"      [U.S. Boxed Warning]:  May cause nephrotoxicity.",
"     </b>",
"     Use with caution in patients with renal impairment; dose adjustment necessary in patients with renal impairment and/or nitrogen retention. Monitor renal function closely; peak serum concentrations should not surpass 20-25 mcg/mL in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parenteral formulation:",
"     <b>",
"      [U.S. Boxed Warning]: Parenteral form should be used only where appropriate audiometric and laboratory testing facilities are available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfite sensitivity:  Formulation contains sodium metabisulfite; may cause allergic reactions including anaphylaxis or asthma exacerbations (some life-threatening) in susceptible patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: I.M. injections should be administered in a large muscle well within the body to avoid peripheral nerve damage and local skin reactions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5722065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Streptomycin crosses the placenta. Many case reports of hearing impairment in children exposed",
"     <i>",
"      in utero",
"     </i>",
"     have been published. Impairment has ranged from mild hearing loss to bilateral deafness. Because of several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy, the manufacturer classifies streptomycin as pregnancy risk factor D.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F223212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3195028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Streptomycin is excreted into breast milk; however, it is not well absorbed when taken orally. This limited oral absorption may minimize exposure to the nursing infant. Nondose-related effects could include modification of bowel flora. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Streptomycin Sulfate Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $22.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F223182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hearing (audiogram), BUN, creatinine; serum concentration of the drug should be monitored in all patients; eighth cranial nerve damage is usually preceded by high-pitched tinnitus, roaring noises, sense of fullness in ears, or impaired hearing and may persist for weeks after drug is discontinued",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F223185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: Peak: 20-30 mcg/mL; Trough: &lt;5 mcg/mL; Toxic: Peak: &gt;50 mcg/mL; Trough: &gt;10 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F223194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ambistryn-S (IN);",
"     </li>",
"     <li>",
"      Estrepto-Monaxin (MX);",
"     </li>",
"     <li>",
"      Estreptomicina (AR);",
"     </li>",
"     <li>",
"      Strepto (TH);",
"     </li>",
"     <li>",
"      Strepto-Hefa (DE);",
"     </li>",
"     <li>",
"      Streptocin (MY);",
"     </li>",
"     <li>",
"      Streptomycinum (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F223171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial protein synthesis by binding directly to the 30S ribosomal subunits causing faulty peptide sequence to form in the protein chain",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F223191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Poorly absorbed; I.M.: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: To extracellular fluid including serum, abscesses, ascitic, pericardial, pleural, synovial, lymphatic, and peritoneal fluids; poorly distributed into CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: ~5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: I.M.: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (29% to 89% as unchanged drug); feces, saliva, sweat, and tears (minimal)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infections, &ldquo;Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1995, 21:9-27.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      1992, 89(1):161-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arguedas AG and Wehrle PP, &ldquo;New Concepts for Antimicrobial Use in Central Nervous System Infections,&rdquo;",
"      <i>",
"       Semin Pediatr Infect Dis",
"      </i>",
"      , 1991, 2(1):36-42.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Balyan FR, Taibah A, De Donato G, et al, &ldquo;Titration Streptomycin Therapy in Meinere's Disease: Long-Term Results,&rdquo;",
"      <i>",
"       Otolaryngol Head Neck Surg",
"      </i>",
"      , 1998, 118(2):261-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/9482564/pubmed\" id=\"9482564\" target=\"_blank\">",
"        9482564",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Begg EJ and Barclay ML, &ldquo;Aminoglycosides - 50 Years On,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1995, 39(6):597-603.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/7654476/pubmed\" id=\"7654476\" target=\"_blank\">",
"        7654476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al, &ldquo;American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2003, 167(4):603-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/12588714/pubmed\" id=\"12588714\" target=\"_blank\">",
"        12588714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Campbell IA, Drobinewski F, Novelli V, et al, &ldquo;Management of Opportunistic Mycobacterial Infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society,&rdquo;",
"      <i>",
"       Thorax",
"      </i>",
"      , 2000, 55(3):210-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/10679540/pubmed\" id=\"10679540\" target=\"_blank\">",
"        10679540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cunha BA, &ldquo;Aminoglycosides: Current Role in Antimicrobial Therapy,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1988, 8(6):334-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/3146747/pubmed\" id=\"3146747\" target=\"_blank\">",
"        3146747",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davidson PT and Le HQ, &ldquo;Drug Treatment of Tuberculosis - 1992,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1992, 43(5):651-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/1379145/pubmed\" id=\"1379145\" target=\"_blank\">",
"        1379145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Tuberculosis,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1993, 35(908):99-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/8412982/pubmed\" id=\"8412982\" target=\"_blank\">",
"        8412982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edson RS and Terrell CL, &ldquo;The Aminoglycosides,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(5):519-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/10319086/pubmed\" id=\"10319086\" target=\"_blank\">",
"        10319086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al, \"An Official ATS/IDSA Statement: Diagnosis, Treatment and Prevention of Nontuberculous Mycobacterial Diseases,&rdquo;",
"      <i>",
"       Am J Resp Crit Care",
"      </i>",
"      , 2007, 175(4):367-416.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Havlir DV and Barnes PF, &ldquo;Tuberculosis in Patients With Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(5):367-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/9929528/pubmed\" id=\"9929528\" target=\"_blank\">",
"        9929528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hmouda H, Laouani-Kechrid C, Karoui M, et al, &ldquo;A Rare Case of Streptomycin-Induced Toxic Epidermal Necrolysis in a Patient With Tuberculosis:  A Therapeutic Dilemma,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(1):165-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/15546942/pubmed\" id=\"15546942\" target=\"_blank\">",
"        15546942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iseman MD, &ldquo;Treatment of Multidrug-Resistant Tuberculosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(11):784-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/8350889/pubmed\" id=\"8350889\" target=\"_blank\">",
"        8350889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim-Sing A, Kays MB, Vivien EJ, et al, &ldquo;Intravenous Streptomycin Use in a Patient Infected With High-Level Gentamicin-Resistant",
"      <i>",
"       Streptococcus faecalis",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1993, 27(6):712-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/8329788/pubmed\" id=\"8329788\" target=\"_blank\">",
"        8329788",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lorin MI, Hsu KH, and Jacob SC, &ldquo;Treatment of Tuberculosis in Children,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1983, 30(2):333-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/6602321/pubmed\" id=\"6602321\" target=\"_blank\">",
"        6602321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morris JT and Cooper RH, &ldquo;Intravenous Streptomycin: A Useful Route of Administration,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1994, 19(6):1150-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/7888550/pubmed\" id=\"7888550\" target=\"_blank\">",
"        7888550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Passeron T, Ndir M, Aubron C, et al, &ldquo;Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Due to Streptomycin,&rdquo;",
"      <i>",
"       Acta Derm Venerol",
"      </i>",
"      , 2004, 84(1):92-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/15040497/pubmed\" id=\"15040497\" target=\"_blank\">",
"        15040497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Prevention and Treatment of Tuberculosis Among Patients Infected With Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations. Centers for Disease Control and Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-20):1-58.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&uuml;tte D, Umboock A, and Pluschke G, &ldquo;Phagocytosis of",
"      <i>",
"       Mycobacterium ulcerans",
"      </i>",
"      in the Course of Rifampicin and Streptomycin Chemotherapy in Buruli Ulcer Lesions,&rdquo;",
"      <i>",
"       Br J  Derm",
"      </i>",
"      , 2009,160(2):273-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/19016694/pubmed\" id=\"19016694\" target=\"_blank\">",
"        19016694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skalsky K, Yahav D, Bishara J, et al, &ldquo;Treatment of Human Brucellosis: Systematic Review and Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2008, 336(7646):701-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/18321957/pubmed\" id=\"18321957\" target=\"_blank\">",
"        18321957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Scoy RE and Wilkowske CJ, &ldquo;Antituberculous Agents,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1992, 67(2):179-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/9/18583/abstract-text/1347579/pubmed\" id=\"1347579\" target=\"_blank\">",
"        1347579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization (WHO), &ldquo;Operational Guidelines on Plague Surveillance, Diagnosis, Prevention and Control,&rdquo; 2010. Available at file://www.searo.who.int/linkfiles/publication_op_guidelines_plague.pdf. Last accessed June 29, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization (WHO), &ldquo;Provisional Guidance on the Role of Specific Antibiotics in the Management of",
"      <i>",
"       Mycobacterium ulcerans",
"      </i>",
"      Disease (Buruli Ulcer),&rdquo; 2004.  Available at file://www.who.int/buruli/en/. Last accessed June 29, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization (WHO), &ldquo;WHO Guidelines on Tularemia,&rdquo; 2007.  Available at: file://whqlibdoc.who.int/publications/2007/9789241547376_eng.pdf. Last accessed June 29, 2012.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10238 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18583=[""].join("\n");
var outline_f18_9_18583=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709418\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14595275\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223222\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223206\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223217\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223207\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223208\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223184\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223168\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223189\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223228\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223188\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14595276\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223230\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223220\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223192\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223172\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300082\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223177\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223180\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722065\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223212\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3195028\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323892\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223182\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223185\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223194\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223171\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223191\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10238\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10238|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/48/40707?source=related_link\">",
"      Streptomycin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/18/26917?source=related_link\">",
"      Streptomycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_9_18584="Vascular malformations of the central nervous system";
var content_f18_9_18584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vascular malformations of the central nervous system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/9/18584/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18584/contributors\">",
"     Robert J Singer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18584/contributors\">",
"     Christopher S Ogilvy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18584/contributors\">",
"     Guy Rordorf, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/9/18584/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18584/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/9/18584/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18584/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/9/18584/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral vascular malformations occur in 0.1 to 4.0 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Four general subtypes of congenital malformations have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Developmental venous anomalies",
"     </li>",
"     <li>",
"      Capillary telangiectasias",
"     </li>",
"     <li>",
"      Cavernous malformations",
"     </li>",
"     <li>",
"      Arteriovenous malformations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Developmental venous anomalies are most common in autopsy series, with an incidence of 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This is followed by arteriovenous malformations (1 percent), capillary malformations (telangiectasias, 0.7 percent), and cavernous malformations (0.4 percent). Developmental venous anomalies and capillary telangiectasia are usually benign, while cavernous malformations and arteriovenous malformations have a greater tendency toward neurologic sequelae.",
"   </p>",
"   <p>",
"    This topic will review our understanding of the natural history and treatment of these three lesions, which continues to evolve with our burgeoning imaging capabilities and clinical experience.",
"   </p>",
"   <p>",
"    Cerebral and spinal cord arteriovenous malformations are discussed separately. Carotid cavernous fistulas are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=see_link\">",
"     \"Brain arteriovenous malformations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H17#H17\">",
"     \"Disorders affecting the spinal cord\", section on 'Vascular malformations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30473?source=see_link\">",
"     \"Carotid-cavernous fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEVELOPMENTAL VENOUS ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental venous anomalies (DVAs), also known as venous angiomas, are composed of a radially arranged configuration of medullary veins (\"caput medusae\") separated by normal brain parenchyma (most commonly white matter) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/5\">",
"     5",
"    </a>",
"    ]. These small venous conduits empty into a central, dilated superficial or deep vein that drains normal brain. A stenosis is common on the collecting vein at the point of penetration into the draining dural sinus. Microscopically, the venous structures appear largely normal with rare degenerative changes consisting of thickening and hyalinization. The lesions are usually supratentorial with a frontal lobe predominance; they do not occur in the diencephalon, brainstem, or spinal cord.",
"   </p>",
"   <p>",
"    DVAs most often are solitary, although multiple lesions have been described in association with other clinical syndromes (eg, the blue rubber bleb nevus syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/6\">",
"     6",
"    </a>",
"    ]. DVAs also may occur concurrently with cavernous malformations in 13 to 40 percent, as well as with other intracranial vascular malformations and with superficial venous malformations of the head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;DVAs are considered benign lesions, although they may uncommonly present with seizures, progressive neurologic deficits, and hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Headache is the most common presenting complaint, followed by seizures and sensory-motor phenomena. However, a direct correlation between these symptoms and the existence of a DVA has not been firmly established [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a ten-year prospective clinical and magnetic resonance imaging study involving 80 patients, a symptomatic hemorrhage rate of 0.34 percent per year was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/13\">",
"     13",
"    </a>",
"    ]. In another study of 93 patients with 492 person-years of follow-up, no symptomatic hemorrhages occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/12\">",
"     12",
"    </a>",
"    ]. The hemorrhages were usually minor, although fatal intracranial hemorrhages have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective case series reviewed the clinical presentations of DVAs in 68 patients whose symptoms could not be attributed to other pathologies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/15\">",
"     15",
"    </a>",
"    ]. Cases with associated cavernous malformations were excluded. Two major pathophysiologic categories of symptomatic DVAs were identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanical compression of intracranial structures by a component of the DVA was seen in 14 patients (21 percent). The most common associated symptoms were hydrocephalus, tinnitus, brainstem deficits, hemifacial spasm, and trigeminal neuralgia.",
"     </li>",
"     <li>",
"      Flow-related symptoms were present in 49 patients (72 percent), with two subcategories:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increased inflow in 19 patients (28 percent), typically related to an arteriovenous malformation (AVM) draining via dilated and ectatic medullary veins through a DVA, resulting parenchymal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intraventricular hemorrhage or venous infarction. Symptoms included headaches, neurologic deficits, seizures, and coma.",
"     </li>",
"     <li>",
"      Restricted outflow, either by an anatomic obstruction (eg, stenosis or thrombosis of the DVA or its draining vein) in 26 patients (38 percent) or by a physiologic obstruction (eg, increased venous pressure secondary to a distal arteriovenous shunt or AVM) in four patients (6 percent). Patients presented with variable combinations of neurologic deficits, headaches, seizures, and altered mentation, a clinical picture that resembled that of cerebral venous thrombosis, with increased intracranial pressure, venous congestive edema,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intraparenchymal or subarachnoid hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No obvious alteration attributable to the DVA was found to explain symptoms in six cases (9 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral angiography is considered the gold standard for the diagnosis of DVAs, but they are usually identified with contrast enhanced cross-sectional imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and magnetic resonance angiography (MRA) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonenhanced CT scans do not usually demonstrate DVAs unless there is an associated cavernous malformation. After contrast administration, the enlarged vein is all that is typically identified. CT angiography (CTA) has also been used to identify DVAs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging and angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI typically shows medullary veins converging on the dilated transcerebral vein. A characteristic \"sunburst\" pattern is seen on enhanced T1-weighted images. Gradient-echo sequences should be included to increase sensitivity for detecting associated cavernous malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/5\">",
"     5",
"    </a>",
"    ]. White matter abnormalities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcifications may be observed in the parenchyma surrounding the DVA. MRA usually demonstrates the dilated venous channel with variable depiction of the smaller medullary veins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned, cerebral angiography usually is not needed for the diagnosis of DVA since axial imaging sequences on MRI often suffice to make the diagnosis. In atypical cases, angiographic findings are pathognomonic; during the late capillary or venous phase there is a paucity of normal veins in the region of the lesion and a characteristic \"caput medusae\" appearance of the radially arranged small medullary veins (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56038 \" href=\"UTD.htm?29/30/30191\">",
"     image 1",
"    </a>",
"    ). The arterial phase is typically normal, however, so-called arterialized DVAs have been described with early phase opacification on angiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enlarged arterial feeders [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/5\">",
"     5",
"    </a>",
"    ]. These lesions may have a bleeding risk that is more similar to an arteriovenous malformation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;DVAs should be treated conservatively in the vast majority of cases, with associated symptoms such as headaches and seizures managed medically [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/14\">",
"     14",
"    </a>",
"    ]. Surgery may be required in the rare patient with hemorrhage associated with a DVA or with uncontrolled seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who undergo surgery, preoperative contrast enhanced imaging is required to identify an associated cavernous malformation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/7\">",
"     7",
"    </a>",
"    ]. Venous infarction has been reported with DVA resection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/17\">",
"     17",
"    </a>",
"    ]; thus, it is reasonable to simply evacuate the hematoma and leave the DVA in situ. Radiosurgical and endovascular techniques do not have a defined role in the management of these lesions.",
"   </p>",
"   <p>",
"    In rare patients who present with symptomatic thrombosis of a DVA, there is anecdotal support for considering the use of systematic anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=see_link\">",
"     \"Treatment and prognosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CAPILLARY TELANGIECTASIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary telangiectasias are small lesions most commonly found in the pons, middle cerebellar peduncles, and dentate nuclei. Multiple lesions are common.",
"   </p>",
"   <p>",
"    The lesions are composed of small, dilated capillaries devoid of smooth muscle or elastic fibers. The intervening brain is often normal; it may also demonstrate areas of microhemorrhage or gliosis. A common histopathological feature of these lesions is a dilated efferent system, probably representing a venous channel.",
"   </p>",
"   <p>",
"    An argument has been made for these lesions representing the early stage in the spectrum of development of cavernous malformations and other \"mixed\" vascular malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Although not proven, angiogenesis is believed to play a role in lesion evolution. Most telangiectasias represent an angiodysplastic phenomenon resulting from faulty embryogenesis of the vascular wall and have been associated with angiomatous phacomatoses such as Osler-Weber-Rendu (hereditary hemorrhagic telangiectasia), Louis-Bar (ataxia-telangiectasia), and Wyburn-Mason (unilateral retinocephalic vascular malformation) syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link&amp;anchor=H13#H13\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\", section on 'Cerebral AVMs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary telangiectasias are usually clinically silent, found incidentally on neuroimaging studies or at postmortem examination. Rare symptomatic cases occur [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/21\">",
"     21",
"    </a>",
"    ]; headache, nausea, and seizures have been described in patients with these lesions, although a causal relationship is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is the most sensitive imaging modality for the identification of capillary telangiectasias. Low signal intensity \"black dots\" on T1 and T2-weighted imaging are suggestive, although not diagnostic of these lesions.",
"   </p>",
"   <p>",
"    Telangiectasias can be identified in the late",
"    <span class=\"nowrap\">",
"     arterial/early",
"    </span>",
"    capillary phase of angiography as a faint blush with an associated venous channel. Thus, these lesions can be distinguished from DVAs that are visualized during the venous phase of the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary telangiectasias are nonoperable lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CAVERNOUS MALFORMATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cavernous malformations (CMs) are also referred to as cavernous angiomas, cavernous hemangiomas, or cavernomas. They may occur sporadically or in a familial pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/22\">",
"     22",
"    </a>",
"    ]. In these populations, de novo lesions have been demonstrated on serial MRIs. The de novo development of CMs after brain biopsy and after radiosurgery confirms the evolutionary nature of the lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three genetic loci (CCM1, CCM2, and CCM3) responsible for familial cavernous malformations have been reported. Nearly all familial cases of cerebral cavernous malformation among Hispanic Americans have been linked to a founder mutation of CCM1 localized to 7q [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Familial cases in white non-Hispanic families have been linked to CCM2 at 7p15-p13 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/27\">",
"     27",
"    </a>",
"    ] and CCM3 at 3q25.2-q27 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On gross examination, cavernous malformations have a characteristic \"mulberry\" appearance with engorged purplish clusters. They vary from 2 mm to several centimeters in diameter. Microscopic examination reveals that CMs are composed of dilated, thin walled capillaries with a simple endothelial lining and a thin, fibrous adventitia. Elastic fibers and smooth muscle are not present in the vessel walls. In the classic description of CMs, there is no intervening brain tissue between the channels of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/29\">",
"     29",
"    </a>",
"    ]. However, this may not be an essential criterion of CMs, as one histopathologic study of 71 CM cases noted intervening brain parenchyma in 50 (70 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/30\">",
"     30",
"    </a>",
"    ], and others have also noted intervening brain tissue in some fraction of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/18,31\">",
"     18,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immediately surrounding tissue is usually gliotic and hemosiderin-laden due to previous hemorrhages. It contains dilated capillaries that may represent telangiectasias; this finding supports the integrative concept of capillary telangiectasias and cavernous malformations representing two ends of a spectrum in the development of cavernous malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/18\">",
"     18",
"    </a>",
"    ]. Inflammation, calcification and, rarely, ossification may be identified with CMs, usually in larger lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Developmental venous anomalies (DVAs) may be associated with CMs. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Developmental venous anomalies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 102 patients, DVAs associated with CMs were found in 23 percent; these occurred more often with lesions in the posterior fossa than the supratentorial compartment [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A later series of 57 patients with CMs found associated DVAs in 25 percent, and atypical patterns of venous drainage associated with CMs were seen in an additional 35 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cerebrum is the most common location for CMs (70 to 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/34\">",
"     34",
"    </a>",
"    ]. They have been reported throughout the supratentorial compartment, but most commonly are subcortical and predisposed to the rolandic and temporal areas. Posterior fossa lesions comprise approximately 25 percent of CMs in most large series, with the majority located in the pons and cerebellar hemispheres. There have been only 36 cases of spinal cord cavernous malformations reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMs occur with equal frequency in males and females, with a mean age of 30 to 40, although women more commonly present with hemorrhage and neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. CMs that are associated with DVAs or atypical venous drainage may be more likely to present with symptomatic hemorrhage than CMs that are not associated with venous anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/33\">",
"     33",
"    </a>",
"    ]. The presentation of CMs is specific to their location.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supratentorial CMs commonly present with hemorrhage, seizures, and progressive neurologic deficits. Annual bleeding rates of 0.25 to 1.1 percent have been reported in several large series [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. Seizures and progressive neurologic deficits may be the result of mass effect and secondary compromise of the microcirculation, or of microhemorrhages with local hemosiderin deposition irritating cortical or subcortical tissue.",
"     </li>",
"     <li>",
"      Infratentorial CMs commonly present with hemorrhage and progressive neurologic deficits. Lesions in the brainstem present with cranial neuropathies and long-tract signs that cause progressive neurologic decline due to the high volume of critical nuclei and fiber tracts in this area. Thus, the natural history of brainstem lesions is worse than that of lesions in other areas. The annual bleeding rate for brainstem lesions is 2 to 3 percent per year, with recurrent hemorrhage rates approaching 17 to 21 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/23\">",
"       23",
"      </a>",
"      ]. Progressive neurologic decline is observed in 39 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The natural history of asymptomatic lesions is significantly different from CMs presenting with clinical sequelae. A prospective study of 122 patients (mean age 37 years, range 4 to 82 years) found that 50 percent were initially asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/39\">",
"     39",
"    </a>",
"    ]. At a mean follow up of 34 months, the hemorrhage rate in asymptomatic and symptomatic patients was 0.6 and 4.5 percent, respectively. In another cohort, five year rates of hemorrhage were 2.4 percent for a first hemorrhage and 29 percent for a recurrent hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/40\">",
"     40",
"    </a>",
"    ]. The risk of recurrent hemorrhage declines over time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. While prior hemorrhage is a consistent risk factor for subsequent hemorrhage, studies have found inconsistent results as to other risk factors for hemorrhage and neurologic disability, including gender, lesion size, location, and multiplicity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/38-42\">",
"     38-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood flow through CMs is minimal. Thus, they may not be seen on angiography and often are referred to as \"angiographically occult.\" Other imaging modalities, particularly MRI, play a more important role in the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI usually establishes the diagnosis of cavernous malformation. Characteristic findings on T-1 and T-2 weighted images include a \"popcorn\" pattern of variable image intensities consistent with evolving blood products (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80348 \" href=\"UTD.htm?37/8/38016\">",
"     image 2",
"    </a>",
"    ). A dark hemosiderin ring, best seen on T2 or gradient echo sequences at the periphery of the lesion, is suggestive of remote hemorrhage (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68000 \" href=\"UTD.htm?34/5/34896\">",
"     image 3",
"    </a>",
"    ). Lesions that mimic CMs on MRI include low grade gliomas, hemorrhagic metastases (particularly melanoma), and choriocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contrast enhanced images should be obtained once a CM is identified in order to delineate any potential associated DVAs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/7\">",
"     7",
"    </a>",
"    ]. Contrast enhanced images often demonstrate DVAs since they are associated with normal flow. On the other hand, CMs may have only scattered enhancement that is variable and inconsequential. This is critical in surgical planning since the resection of DVAs may compromise normal cortical venous drainage patterns and lead to venous infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT usually demonstrates a nonspecific, irregular, hyperdense mass with variable degrees of calcification. A faint perilesional blush with contrast administration is a variable and nonspecific finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMs demonstrate a capillary blush or early draining vein in approximately 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/34\">",
"     34",
"    </a>",
"    ]. These findings may be similar to the angiographic appearance of meningiomas. Digital subtraction angiography appears to be much more sensitive than MRI for detecting the presence of CM-associated atypical venous drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic CMs are observed, irrespective of location. Indications for surgical resection of accessible symptomatic cerebral and cerebellar lesions include progressive neurologic deficit, intractable epilepsy, and recurrent hemorrhage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One group reported excellent or good surgical outcomes in 97 percent of 65 patients with cerebral and cerebellar CMs at a mean follow-up of one year [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/34\">",
"       34",
"      </a>",
"      ]. A poor outcome was reported in 1.5 percent with an overall mortality of 1.5 percent.",
"     </li>",
"     <li>",
"      In a case series of 168 patients with symptomatic epilepsy attributed to CM, more than two-thirds of patients were seizure free at three years after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/43\">",
"       43",
"      </a>",
"      ]. Predictors for good outcome included mesiotemporal location, size &lt;1.5 cm, and the absence of secondarily generalized seizures.",
"     </li>",
"     <li>",
"      Another series identified a long preoperative seizure history and poorer preoperative seizure control as unfavorable prognostic indicators [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Surgically inaccessible lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic CMs entirely surrounded by eloquent tissue (eg, rolandic cortex, brainstem,",
"    <span class=\"nowrap\">",
"     thalamus/basal",
"    </span>",
"    ganglia) are usually observed despite the poor natural history associated with untreated brainstem and thalamic lesions.",
"   </p>",
"   <p>",
"    Stereotactic radiosurgery is a potential alternative to conservative therapy in patients with such surgically inaccessible lesions, and the available evidence suggests that it does lead to a reduction in hemorrhage, especially two years or more after radiosurgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Nevertheless, high complication rates in available published series coupled with clinical experience has dissuaded many from using stereotactic radiosurgery for the treatment of CMs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/32/2566?source=see_link&amp;anchor=H5#H5\">",
"     \"Complications of cranial stereotactic radiosurgery\", section on 'Late reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, one retrospective analysis of 95 patients with 98 lesions found that stereotactic radiosurgery was associated with a significant drop in the annualized hemorrhage rate from 17 to 5 percent after a two-year post-treatment latency period [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/46\">",
"     46",
"    </a>",
"    ]. However, at an average follow-up of 5.4 years, the incidence of permanent neurologic deficit and mortality was 16 and 3 percent, respectively, and these complications were attributed to radiation-induced injury. In addition, the combined effects of radiation-related injury and clinical progression of the lesion led to a significant decline in neurologic function during follow-up.",
"   </p>",
"   <p>",
"    Given the available data, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    using stereotactic radiosurgery for the treatment of CMs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Brainstem location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brainstem CMs often are treated due to their aggressive natural history when there is progressive neurologic deterioration, with or without recurrent hemorrhage, if the lesion lies near the pial surface or if a non-eloquent tissue corridor exists to the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/49\">",
"     49",
"    </a>",
"    ]. In one series of 23 patients with surgically treated brainstem CMs, 46 percent had transient neurologic deficits, 17 percent had new or worsened deficits, and 83 percent were significantly improved at a mean follow-up of 3.9 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/35\">",
"     35",
"    </a>",
"    ]. In a second retrospective analysis, no or only slight neurologic deficit was reported in 67 percent of 30 patients treated conservatively compared with 84 percent of 93 patients treated surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/23\">",
"     23",
"    </a>",
"    ]. Microsurgical techniques are also being used with success in some centers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18584/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ARTERIOVENOUS MALFORMATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriovenous malformations (AVMs) are the most dangerous congenital vascular malformations. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=see_link\">",
"     \"Brain arteriovenous malformations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/42/26274?source=see_link\">",
"       \"Patient information: Arteriovenous malformations in the brain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26648821\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four general types of congenital cerebral vascular malformations have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Developmental venous anomalies or venous angiomas are the most common and consist of a radially arranged configuration of medullary veins (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Developmental venous anomalies'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The lesions are usually supratentorial and solitary but can be multiple and occur with cavernous malformations.",
"     </li>",
"     <li>",
"      They are usually identified on magnetic resonance imaging (MRI). Cerebral angiography is considered the gold standard for diagnosis.",
"     </li>",
"     <li>",
"      Usually an incidental finding, rarely present with seizures or hemorrhage. After diagnosis, hemorrhage is unusual.",
"     </li>",
"     <li>",
"      Most patients are followed without intervention, rarely surgery is required for hemorrhage or intractable epilepsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Capillary telangiectasias are small lesions most commonly found in the pons, middle cerebellar peduncles, and dentate nuclei. Multiple lesions are common (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Capillary telangiectasias'",
"      </a>",
"      above.).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      These are usually incidental findings on MRI.",
"     </li>",
"     <li>",
"      They are not associated with morbidity and intervention is not required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cavernous malformations (cavernous angiomas, cavernomas) may occur as a sporadic or familial condition. These are thin walled dilated capillaries with a simple endothelial lining. Associated developmental venous anomalies occur in about 25 percent. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cavernous malformations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      They can occur throughout the brain but are most common in the subcortical rolandic and temporal areas.",
"     </li>",
"     <li>",
"      Clinical presentation can include hemorrhage, seizures,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progressive neurologic deficits. Annual bleeding rates are up to 1 percent per year for supratentorial lesions and up to 3 percent per year for brainstem lesions. Recurrent hemorrhage is more common after an initial bleed and may be as high as 5 percent per year for supratentorial lesions and 21 percent for brainstem lesions.",
"     </li>",
"     <li>",
"      Cavernous malformations are typically identified on MRI and are often angiographically occult.",
"     </li>",
"     <li>",
"      Asymptomatic cavernous malformations are followed without intervention. Surgical resection may be indicated for progressive neurologic deficits, intractable epilepsy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemorrhage. Stereotactic radiosurgery is an option for nonoperable lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AVMs are the most dangerous cerebral vascular malformation and can cause hemorrhage, seizures, headaches and focal neurologic deficits. These lesions are discussed in detail separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=see_link\">",
"       \"Brain arteriovenous malformations\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/1\">",
"      el-Gohary EG, Tomita T, Gutierrez FA, McLone DG. Angiographically occult vascular malformations in childhood. Neurosurgery 1987; 20:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/2\">",
"      McCormick WF. The pathology of vascular (\"arteriovenous\") malformations. J Neurosurg 1966; 24:807.",
"     </a>",
"    </li>",
"    <li>",
"     McCormick, WF. Pathology of vascular malformations of the brain. In: Intracranial Arteriovenous Malformations, Wilson, CB, Stein, BM (Eds), William &amp; Wilkins, Baltimore, MD 1984. p.44.",
"    </li>",
"    <li>",
"     Russell, DS, Rubinstein, LJ. Pathology of Tumors of the Nervous System. 5th ed. Williams &amp; Wilkins, Baltimore, MD 1989. p.727.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/5\">",
"      Ru&iacute;z DS, Yilmaz H, Gailloud P. Cerebral developmental venous anomalies: current concepts. Ann Neurol 2009; 66:271.",
"     </a>",
"    </li>",
"    <li>",
"     Osborn, AG. Intracranial vascular malformations. In: Diagnostic Neuroradiology, Osborn, AG (Ed), Mosby Year-Book, St. Louis 1994. p.316.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/7\">",
"      Abe T, Singer RJ, Marks MP, et al. Coexistence of occult vascular malformations and developmental venous anomalies in the central nervous system: MR evaluation. AJNR Am J Neuroradiol 1998; 19:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/8\">",
"      Boukobza M, Enjolras O, Guichard JP, et al. Cerebral developmental venous anomalies associated with head and neck venous malformations. AJNR Am J Neuroradiol 1996; 17:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/9\">",
"      Numaguchi Y, Kitamura K, Fukui M, et al. Intracranial venous angiomas. Surg Neurol 1982; 18:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/10\">",
"      Rothfus WE, Albright AL, Casey KF, et al. Cerebellar venous angioma: \"benign\" entity? AJNR Am J Neuroradiol 1984; 5:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/11\">",
"      Malik GM, Morgan JK, Boulos RS, Ausman JI. Venous angiomas: an underestimated cause of intracranial hemorrhage. Surg Neurol 1988; 30:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/12\">",
"      Hon JM, Bhattacharya JJ, Counsell CE, et al. The presentation and clinical course of intracranial developmental venous anomalies in adults: a systematic review and prospective, population-based study. Stroke 2009; 40:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/13\">",
"      McLaughlin MR, Kondziolka D, Flickinger JC, et al. The prospective natural history of cerebral venous malformations. Neurosurgery 1998; 43:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/14\">",
"      Garner TB, Del Curling O Jr, Kelly DL Jr, Laster DW. The natural history of intracranial venous angiomas. J Neurosurg 1991; 75:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/15\">",
"      Pereira VM, Geibprasert S, Krings T, et al. Pathomechanisms of symptomatic developmental venous anomalies. Stroke 2008; 39:3201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/16\">",
"      Peebles TR, Vieco PT. Intracranial developmental venous anomalies: diagnosis using CT angiography. J Comput Assist Tomogr 1997; 21:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/17\">",
"      Senegor M, Dohrmann GJ, Wollmann RL. Venous angiomas of the posterior fossa should be considered as anomalous venous drainage. Surg Neurol 1983; 19:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/18\">",
"      Rigamonti D, Johnson PC, Spetzler RF, et al. Cavernous malformations and capillary telangiectasia: a spectrum within a single pathological entity. Neurosurgery 1991; 28:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/19\">",
"      Maeder P, Gudinchet F, Meuli R, de Tribolet N. Development of a cavernous malformation of the brain. AJNR Am J Neuroradiol 1998; 19:1141.",
"     </a>",
"    </li>",
"    <li>",
"     Garcia, J, Anderson, M. Circulatory disorders and their effects on the brain. In: Textbook of neuropathology, Davis, R, Robertson, D (Eds), Williams &amp; Wilkins, Baltimore 1991. p.625.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/21\">",
"      Farrell DF, Forno LS. Symptomatic capillary telangiectasis of the brainstem without hemorrhage. Report of an unusual case. Neurology 1970; 20:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/22\">",
"      Rigamonti D, Hadley MN, Drayer BP, et al. Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med 1988; 319:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/23\">",
"      Fritschi JA, Reulen HJ, Spetzler RF, Zabramski JM. Cavernous malformations of the brain stem. A review of 139 cases. Acta Neurochir (Wien) 1994; 130:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/24\">",
"      Dubovsky J, Zabramski JM, Kurth J, et al. A gene responsible for cavernous malformations of the brain maps to chromosome 7q. Hum Mol Genet 1995; 4:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/25\">",
"      Laberge-le Couteulx S, Jung HH, Labauge P, et al. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet 1999; 23:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/26\">",
"      Verlaan DJ, Davenport WJ, Stefan H, et al. Cerebral cavernous malformations: mutations in Krit1. Neurology 2002; 58:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/27\">",
"      Craig HD, G&uuml;nel M, Cepeda O, et al. Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27. Hum Mol Genet 1998; 7:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/28\">",
"      Bergametti F, Denier C, Labauge P, et al. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 2005; 76:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/29\">",
"      Raychaudhuri R, Batjer HH, Awad IA. Intracranial cavernous angioma: a practical review of clinical and biological aspects. Surg Neurol 2005; 63:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/30\">",
"      Frischer JM, Pipp I, Stavrou I, et al. Cerebral cavernous malformations: congruency of histopathological features with the current clinical definition. J Neurol Neurosurg Psychiatry 2008; 79:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/31\">",
"      Tomlinson FH, Houser OW, Scheithauer BW, et al. Angiographically occult vascular malformations: a correlative study of features on magnetic resonance imaging and histological examination. Neurosurgery 1994; 34:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/32\">",
"      Runnels JB, Gifford DB, Forsberg PL, Hanbery JW. Dense calcification in a large cavernous angioma. Case report. J Neurosurg 1969; 30:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/33\">",
"      Kamezawa T, Hamada J, Niiro M, et al. Clinical implications of associated venous drainage in patients with cavernous malformation. J Neurosurg 2005; 102:24.",
"     </a>",
"    </li>",
"    <li>",
"     McCormick, PC, Michelson, WJ. Management of intracranial cavernous and venous malformations. In: Intracranial Vascular Malformations, Barrow, DL (Ed), American Association of Neurological Surgeons. Park Ridge, IL 1990. p.197.",
"    </li>",
"    <li>",
"     Tew, JM, Sathi, S. Cavernous Malformations. In: Primer on Cerebrovascular Diseases, Welch, KM, Caplan, LR, Reis, DJ, et al. (Eds), Academic Press. San Diego, CA 1997. p.550.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/36\">",
"      Del Curling O Jr, Kelly DL Jr, Elster AD, Craven TE. An analysis of the natural history of cavernous angiomas. J Neurosurg 1991; 75:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/37\">",
"      Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma. J Neurosurg 1991; 75:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/38\">",
"      Aiba T, Tanaka R, Koike T, et al. Natural history of intracranial cavernous malformations. J Neurosurg 1995; 83:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/39\">",
"      Kondziolka D, Lunsford LD, Kestle JR. The natural history of cerebral cavernous malformations. J Neurosurg 1995; 83:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/40\">",
"      Al-Shahi Salman R, Hall JM, Horne MA, et al. Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol 2012; 11:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/41\">",
"      Flemming KD, Link MJ, Christianson TJ, Brown RD Jr. Prospective hemorrhage risk of intracerebral cavernous malformations. Neurology 2012; 78:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/42\">",
"      Robinson JR Jr, Awad IA, Magdinec M, Paranandi L. Factors predisposing to clinical disability in patients with cavernous malformations of the brain. Neurosurgery 1993; 32:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/43\">",
"      Baumann CR, Acciarri N, Bertalanffy H, et al. Seizure outcome after resection of supratentorial cavernous malformations: a study of 168 patients. Epilepsia 2007; 48:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/44\">",
"      Cohen DS, Zubay GP, Goodman RR. Seizure outcome after lesionectomy for cavernous malformations. J Neurosurg 1995; 83:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/45\">",
"      Kondziolka D, Lunsford LD, Flickinger JC, Kestle JR. Reduction of hemorrhage risk after stereotactic radiosurgery for cavernous malformations. J Neurosurg 1995; 83:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/46\">",
"      Amin-Hanjani S, Ogilvy CS, Candia GJ, et al. Stereotactic radiosurgery for cavernous malformations: Kjellberg's experience with proton beam therapy in 98 cases at the Harvard Cyclotron. Neurosurgery 1998; 42:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/47\">",
"      Hasegawa T, McInerney J, Kondziolka D, et al. Long-term results after stereotactic radiosurgery for patients with cavernous malformations. Neurosurgery 2002; 50:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/48\">",
"      Liu KD, Chung WY, Wu HM, et al. Gamma knife surgery for cavernous hemangiomas: an analysis of 125 patients. J Neurosurg 2005; 102 Suppl:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/49\">",
"      Zimmerman RS, Spetzler RF, Lee KS, et al. Cavernous malformations of the brain stem. J Neurosurg 1991; 75:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18584/abstract/50\">",
"      Sandalcioglu IE, Wiedemayer H, Secer S, et al. Surgical removal of brain stem cavernous malformations: surgical indications, technical considerations, and results. J Neurol Neurosurg Psychiatry 2002; 72:351.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1129 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18584=[""].join("\n");
var outline_f18_9_18584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26648821\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEVELOPMENTAL VENOUS ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Magnetic resonance imaging and angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CAPILLARY TELANGIECTASIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CAVERNOUS MALFORMATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Surgically inaccessible lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Brainstem location",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ARTERIOVENOUS MALFORMATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26648821\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1129\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1129|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/30/30191\" title=\"diagnostic image 1\">",
"      DVA angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/8/38016\" title=\"diagnostic image 2\">",
"      Cavernous malformation MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/5/34896\" title=\"diagnostic image 3\">",
"      Cavernous malformation bleed",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=related_link\">",
"      Brain arteriovenous malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30473?source=related_link\">",
"      Carotid-cavernous fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/32/2566?source=related_link\">",
"      Complications of cranial stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/42/26274?source=related_link\">",
"      Patient information: Arteriovenous malformations in the brain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=related_link\">",
"      Treatment and prognosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_9_18585="Natural history and diagnosis of cardiac allograft vasculopathy";
var content_f18_9_18585=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natural history and diagnosis of cardiac allograft vasculopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/9/18585/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18585/contributors\">",
"     Finn Gustafsson, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/9/18585/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18585/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/9/18585/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18585/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/9/18585/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12357152\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac transplantation is the definitive therapy for eligible patients with end-stage heart failure. The major limitations to survival in the early post-transplant period (first six months) are nonspecific graft failure, acute rejection, and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/1\">",
"     1",
"    </a>",
"    ]. Beyond the first year, cardiac allograft vasculopathy (CAV, also called transplant coronary artery disease or cardiac transplant vasculopathy) is the second most common cause of death, after malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=see_link&amp;anchor=H9#H9\">",
"     \"Prognosis after cardiac transplantation\", section on 'Causes of death'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CAV typically leads to ischemic consequences including graft failure, arrhythmias and sudden death. CAV may cause myocardial infarction, but because of cardiac denervation it only rarely causes angina. The epidemiology, approach to the diagnosis of transplant vasculopathy, as well as outcome, will be reviewed here. The pathogenesis, prevention and treatment of transplant vasculopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link\">",
"     \"Prevention and treatment of cardiac allograft vasculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=see_link\">",
"     \"Pathogenesis of and risk factors for cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12357181\">",
"    <span class=\"h1\">",
"     DEFINITIONS AND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence and prognosis of CAV after cardiac transplantation vary considerably depending on how vasculopathy is defined and which method is used to detect it. Some studies have defined CAV as coronary artery stenosis ranging from 30 to 70 percent by coronary angiography. Other studies have diagnosed CAV using the much more sensitive technique of intravascular ultrasound.",
"   </p>",
"   <p>",
"    To resolve the problem of disparate definitions of CAV, guidelines for terminology related to CAV were published by the International Society of Heart and Lung Transplantation (ISHLT) in July 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/2\">",
"     2",
"    </a>",
"    ]. The consensus of the ISHLT working group was to base the definition and diagnosis of transplant vasculopathy on conventional invasive coronary angiography. A grading system based on angiographic findings and graft function (evaluated by echocardiography or invasive hemodynamic data) was established (",
"    <a class=\"graphic graphic_table graphicRef70548 \" href=\"UTD.htm?9/14/9452\">",
"     table 1",
"    </a>",
"    ). It is hoped that adoption of uniform definitions will advance the understanding and, in turn, prevention and treatment of cardiac transplant vasculopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12357188\">",
"    <span class=\"h1\">",
"     PREVALENCE AND INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2009 ISHLT registry report on data from more than 84,000 heart transplant recipients, the overall prevalence of CAV in survivors at 1, 5, and 10 years after transplantation was 8, 30, and 51 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/3\">",
"     3",
"    </a>",
"    ]. The incidence of vasculopathy has decreased slightly, but significantly, from the period 1994 to 2000 to the period 2001 to 2007. In the ISHLT registry, important predictors of development of CAV were higher donor age, a donor history of hypertension, younger recipient age, number of HLA-DR mismatches and recipient pretransplant diagnosis of ischemic heart disease. These findings were confirmed in a recent analysis of donor factors predicting CAV in 39704 heart transplant recipients from the United Network for Organ Sharing (UNOS). The prevalence of CAV at five years was somewhat lower than in the ISHLT registry (23 percent). In the UNOS population, donor sex, ethnicity, tobacco use, diabetes and weight also predicted early vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/4\">",
"     4",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    However, the studies mentioned above do not address the severity of CAV. The frequency of clinically-important disease was examined in a multicenter analysis of CAV performed by the Cardiac Transplant Research Database, which evaluated 4637 angiograms in 2609 patients transplanted between 1990 and 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/5\">",
"     5",
"    </a>",
"    ]. At five years, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some angiographic evidence of coronary disease was present in 42 percent of patients. However, only 7 percent had severe coronary disease, which was defined as left main coronary artery stenosis &gt;70 percent, stenosis of two or more primary coronary arteries &gt;70 percent, or branch stenosis in all three systems &gt;70 percent.",
"     </li>",
"     <li>",
"      Death or retransplantation due to coronary disease occurred in 7 percent overall, but occurred in two-thirds of those with severe coronary disease. (See",
"      <a class=\"local\" href=\"#H12357195\">",
"       'Prognosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CAV is typically slowly progressive. However, occasionally patients progress rapidly and unpredictably [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. In a matter of months, the angiographic picture can change from a relatively benign appearance to a diffuse, occlusive pattern. A lower incidence of CAV (22 percent) has been observed in patients who survive more than 10 years, suggesting that late onset CAV is infrequent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/11\">",
"     11",
"    </a>",
"    ], although this conclusion is controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12357195\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advancing CAV ultimately results in heart failure and death due to ventricular dysfunction or arrhythmias. In some patients sudden death may be the first symptom of CAV. Sudden death in transplant recipients with CAV can occur even in patients who have functioning implantable defibrillators in place, and mechanisms other than ventricular arrhythmias may be responsible for sudden cardiac death in this population, most likely rapidly-developing pump failure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/12\">",
"     12",
"    </a>",
"    ]. There is a paucity of data on the risk of developing graft failure and ventricular arrhythmias in patients with angiographic evidence of CAV.",
"   </p>",
"   <p>",
"    Angiographically significant CAV is associated with a high mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. In an older report of 54 patients with at least 40 percent stenosis in one or more coronary arteries, overall survival was 67, 44, and 17 percent at one, two, and five years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/13\">",
"     13",
"    </a>",
"    ]. Survival varied with disease severity, being worst in patients with three vessel disease (13 percent at two years).",
"   </p>",
"   <p>",
"    The 2009 ISHLT Registry report noted that allograft CAV and late graft failure (likely due to CAV) were responsible for 33 percent of all deaths five years after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/3\">",
"     3",
"    </a>",
"    ]. This proportion remained fairly constant when mortality rates were assessed at 5 to 10 and &gt;10 years after transplant. In patients who survived the first year after transplantation, the strongest predictor of death five years after transplant was presence of transplant coronary disease at year one (relative risk 1.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/3\">",
"     3",
"    </a>",
"    ]. There appears to be some improvement in the prognosis of patients with CAV in more recent eras. In the 2009 report from the ISHLT, a small (2 to 4 percent), but significant improvement was seen in survival of patients with CAV when comparing patients who were transplanted between 1994 and 2000 to those transplanted between 2001 and 2007. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=see_link&amp;anchor=H9#H9\">",
"     \"Prognosis after cardiac transplantation\", section on 'Causes of death'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12357202\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CAV is difficult to establish based upon clinical evaluation. Cardiac transplant recipients have both afferent and efferent denervation. Although there is evidence for reinnervation in some patients by five years after transplantation, the degree of reinnervation is generally incomplete [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. As a result, patients with CAV seldom experience the classic angina pectoris.",
"   </p>",
"   <p>",
"    Silent myocardial infarction, sudden death, and progressive heart failure are common presentations of CAV. CAV may also present with asymptomatic EKG changes, or changes in allograft function detected on routine echocardiography or right heart catheterization. Premonitory symptoms associated with exertion, such as chest pain, dyspnea, diaphoresis, gastrointestinal distress, presyncope, or syncope, are often missing or atypical, so symptoms do not provide a reliable warning of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, if outcomes are to be improved by early diagnosis, CAV must be detected by screening studies rather than by waiting for the onset of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20449897\">",
"    <span class=\"h2\">",
"     Invasive imaging studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12357209\">",
"    <span class=\"h3\">",
"     Coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the 2010 ISHLT consensus statement advocates use of invasive coronary angiography as the standard of surveillance and monitoring of transplant vasculopathy. In most transplant centers the diagnosis of allograft vasculopathy is established by prospective angiographic monitoring. Baseline coronary angiography is commonly performed a few weeks after transplantation unless the donor underwent catheterization as part of the evaluation of the suitability of the organ, and at most centers it is performed annually or biannually starting at one year postoperatively.",
"   </p>",
"   <p>",
"    Coronary angiography enables identification of coronary luminal narrowing, lesion type as well as assessment of the rate of contrast filling of the coronary arteries. A standardized description of lesion type was suggested by Gao et al. and subsequently adopted generally (",
"    <a class=\"graphic graphic_figure graphicRef69520 \" href=\"UTD.htm?8/19/8511\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/17\">",
"     17",
"    </a>",
"    ]. The description is useful for communicating angiography results in heart transplant recipients, but the classification has not been shown to be of prognostic value. The rate of contrast filling of the coronary arteries provides an important clue for detecting small vessel and distal disease. Coronary artery spasm may mimic diffuse vessel narrowing caused by CAV and lead to an erroneous diagnosis of CAV. If spasm is suspected, intracoronary injection of 200 &micro;g",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    will usually resolve it.",
"   </p>",
"   <p>",
"    Since transplant vasculopathy is a diffuse process, angiographic diagnosis of CAV is often more difficult than for nontransplant coronary atherosclerotic lesions. Consequently, the interobserver variation of angiographic diagnoses of coronary vasculopathy is large [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/18\">",
"     18",
"    </a>",
"    ]. Angiograms performed to screen for allograft vasculopathy should be reviewed by investigators with particular experience in the field. Although coronary angiography is the clinical gold standard for the diagnosis of nontransplant coronary artery disease, it is less sensitive in detecting transplant vasculopathy, as acknowledged in the ISHLT consensus document [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/2,7,10,19,20\">",
"     2,7,10,19,20",
"    </a>",
"    ]. The lower sensitivity of angiography for CAV is due to the often diffuse, longitudinal and concentric nature of the disease, as opposed to the focal and eccentric pattern of nontransplant atherosclerosis (",
"    <a class=\"graphic graphic_figure graphicRef51137 \" href=\"UTD.htm?28/45/29395\">",
"     figure 2",
"    </a>",
"    ). As a result, many patients who develop clinical events that are presumably due to transplant vasculopathy do not have angiographically significant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of preventive therapy in patients at risk for contrast nephropathy (particularly diabetic patients with renal dysfunction) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27764987\">",
"    <span class=\"h3\">",
"     Additional invasive evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of these limitations, adjuncts to angiography have been sought that might improve the detection of early transplant vasculopathy. These include the Thrombolysis in Myocardial Infarction (TIMI) frame count, Doppler measurement of coronary flow reserve, and, in some centers, intravascular ultrasound imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27764994\">",
"    <span class=\"h4\">",
"     TIMI frame count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI frame count, which is the number of cine frames required for dye to reach standardized distal coronary landmarks during coronary angiography, is a simple and reproducible method for identifying a decrease in rate of coronary blood flow on routine angiograms. Worsening microvascular function signified by increasing TIMI frame count may or may not correlate with progression of epicardial disease. In a study of 42 cardiac transplant recipients followed for five years, an increase in the TIMI frame count was observed in those who developed angiographic evidence of transplant atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/23\">",
"     23",
"    </a>",
"    ]. On the other hand, a later study of 52 patients followed for a mean of 4.3 years found no correlation between TIMI frame count and progression of CAV by intravascular ultrasound (IVUS) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H5#H5\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI frame count'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27765001\">",
"    <span class=\"h4\">",
"     Coronary flow reserve",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intracoronary wire tipped with a Doppler ultrasound transducer can measure the velocity of coronary artery blood flow as well as coronary flow reserve, which is the increase in coronary blood flow in response to a vasodilator such as adenosine. Measurement of coronary artery flow reserve may provide additional information about the presence and severity of transplant vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients with vasculopathy are more likely to have reduced coronary artery flow reserve compared to those without evidence of vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=see_link\">",
"     \"Clinical use of coronary artery pressure and Doppler flow measurements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12357216\">",
"    <span class=\"h4\">",
"     Intravascular ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular (intracoronary) ultrasound (IVUS) with or without quantitative coronary angiography (QCA) has been adopted by several cardiac transplant centers as the diagnostic approach of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Since the intimal and medial layers of the arterial wall have differing acoustical densities, IVUS can distinguish these layers and thereby detect abnormal thickening of the intima.",
"   </p>",
"   <p>",
"    IVUS detects intimal thickening in more than 80 percent of patients as early as one year after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The most rapid rate of intimal thickening occurs in the first year after transplantation, followed by a slower rate of thickening [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/28\">",
"     28",
"    </a>",
"    ]. Since CAV is frequently diffuse and circumferential, many patients with moderate to severe intimal thickening on IVUS, including those who develop clinical events, do not have significant visible disease on coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/20-22\">",
"     20-22",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_movie graphicRef65796 \" href=\"UTD.htm?7/59/8113\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef77518 \" href=\"UTD.htm?38/1/38929\">",
"     movie 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In proximal segments of the coronary arteries, the intimal thickening is primarily focal and eccentric, similar to the pattern seen in native coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In comparison, intimal thickening in mid and distal segments is more commonly diffuse and circumferential. This suggests at least two etiologies for the vascular lesions: proximal disease that may be donor-transmitted; and distal disease that may be the result of acquired immune-mediated vessel injury exacerbated by significant metabolic perturbations that occur after transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. The only possible way to distinguish between donor transmitted disease and de-novo allograft vasculopathy is by performing serial IVUS studies starting with a baseline measurement early postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/32\">",
"     32",
"    </a>",
"    ]. The prognostic utility of intimal thickening detected by IVUS will be discussed in the section immediately below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12357223\">",
"    <span class=\"h3\">",
"     Predictive value of invasive evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of CAV by angiography or TIMI frame count has prognostic as well as diagnostic value. Although coronary angiography has relatively low sensitivity for CAV, the presence of angiographic disease is prognostically significant. For example, a study of 91 patients found that absence of angiographic coronary disease was a significant predictor of survival without adverse cardiac events at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TIMI frame count appears to also have predictive value. Worsening global TIMI frame count (the mean TIMI FC for the three coronary arteries) from baseline to one year was associated with increased mortality rate during mean 4.3-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/24\">",
"     24",
"    </a>",
"    ]. The potential prognostic value of coronary flow reserve in transplant recipients remains to be determined.",
"   </p>",
"   <p>",
"    Abnormalities detected by IVUS are predictive of cardiac events and death as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early study, the presence of severe intimal thickening (&gt;0.5 mm) detected by IVUS predicted subsequent adverse cardiac events, which often occurred in patients with normal coronary angiograms [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IVUS evidence of progression of CAV during the first year after transplantations is a predictor of adverse events as illustrated by the following studies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a multicenter study of 125 patients, the change in maximal intimal thickness (MIT) from baseline to one year was compared at several matched sites in the same coronary artery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/34\">",
"       34",
"      </a>",
"      ]. An increase in MIT of &ge;0.5 mm was present in 24 patients (19 percent). At five-year follow-up, these 24 patients had more frequent death or graft loss (20.8 versus 5.9 percent in those with an MIT increase &lt; 0.5 mm), nonfatal major adverse cardiac events, death or graft loss (45.8 versus 16.8 percent), and newly occurring angiographic luminal irregularities (65.2 versus 32.6 percent).",
"     </li>",
"     <li>",
"      Similar findings were noted in a series of 143 patients in which MIT on IVUS was measured at baseline and one year; rapidly progressive vasculopathy was again defined as an increase in MIT of &ge;0.5 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/21\">",
"       21",
"      </a>",
"      ]. Rapid progression by IVUS was noted in 54 patients (37 percent) at one year after transplant. At 5.9-year follow-up, patients with rapid progression at one year had significantly higher rates of mortality (26 versus 11 percent in those with an MIT increase of less than 0.5 mm), the combined endpoint of death or myocardial infarction (51 versus 16 percent), as well as angiographic disease (22 and 2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations confirm the utility of IVUS assessment of cardiac allograft vasculopathy and as a prognostic indicator in cardiac transplant recipients. These data have led to use of IVUS as a surrogate endpoint in clinical trials of new immunosuppressive and other agents known to affect intimal proliferation. In experienced hands, the risk associated with IVUS in transplant recipients is low [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/35\">",
"     35",
"    </a>",
"    ], but the exam is time consuming and adds to cost.",
"   </p>",
"   <p>",
"    Consequently, as noted in the ISHLT consensus statement, IVUS is not recommended for routine surveillance outside of clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition to its value in research, IVUS may be of clinical value in selected patients in identifying the cause of unexplained graft failure (ie, in the absence of rejection) patients with normal coronary arteriography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12357230\">",
"    <span class=\"h2\">",
"     Noninvasive studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive studies have not proven sufficiently sensitive to replace coronary angiography in the early years after cardiac transplantation, although they may serve a useful adjunctive role in detecting myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/36\">",
"     36",
"    </a>",
"    ]. Some transplant programs follow selected low-risk patients (ie, those with normal angiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IVUS at five years) with noninvasive techniques. If the noninvasive evaluation is not normal, patients require evaluation by invasive coronary angiography.",
"   </p>",
"   <p>",
"    Conventional ECG stress testing is of little value in heart transplant recipients, since resting ECG abnormalities are frequently present.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    &nbsp;stress echocardiography is the best validated technique correlating with prognosis in cardiac transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Stress radionuclide myocardial perfusion imaging with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    &nbsp;or dobutamine is an alternative approach [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. Data are more limited on the value of PET scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/45\">",
"     45",
"    </a>",
"    ]. In the last few years, multiple studies have evaluated the use of CT angiography as a potentially attractive, noninvasive method for transplant vasculopathy surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/45-54\">",
"     45-54",
"    </a>",
"    ]. In addition, experimental techniques, such as contrast enhanced echocardiographic assessment of coronary flow reserve are being tested in clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Finally, assessments of microvascular pathology on routine endomyocardial biopsies (obtained as surveillance for rejection) and plasma biomarkers have recently been proposed as possible adjunct diagnostic modalities in vasculopathy surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to its ancillary role in the early years after transplantation, noninvasive screening is generally performed late (more than five years) after transplantation when the incidence of new, aggressive disease decreases to some extent, or when renal dysfunction increases the risk of contrast nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12357237\">",
"    <span class=\"h3\">",
"     Dobutamine echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential value of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    &nbsp;stress echocardiography (DSE) was illustrated in a study of 109 transplant recipients in whom yearly DSE was performed at the time of angiography and IVUS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/39\">",
"     39",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sensitivity of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiography for CAV was 85 percent, using angiography and IVUS as the gold standard.",
"     </li>",
"     <li>",
"      There were no events in the patients with negative 2D and M-mode",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress studies, suggesting an excellent negative predictive value.",
"     </li>",
"     <li>",
"      Serial deterioration on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiogram was associated with an increased risk of events compared to no deterioration (relative risk 7.3).",
"     </li>",
"     <li>",
"      The prognostic value of DSE was comparable to that of IVUS and angiography.",
"     </li>",
"     <li>",
"      The presence of cardiac sensory denervation in heart transplants can affect the symptoms associated with ischemia, the occurrence of arrhythmia, and the potential for hypotension associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      . Despite these concerns, dobutamine stress appears to be safe in cardiac transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/60\">",
"       60",
"      </a>",
"      ]. However, it should be performed with caution in patients suspected of having severe transplant vasculopathy. These patients should likely be referred directly for coronary angiography. Coronary arteriography should be performed promptly in patients with symptoms suggestive of transplant vasculopathy, even if dobutamine stress echocardiogram results are normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contrast enhanced transthoracic Doppler echocardiography using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress to assess coronary flow reserve in the left anterior descending coronary artery has been investigated as a possible screening tool for allograft vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. However, this technique requires high-quality imaging, which may not be feasible in many heart transplant patients due to suboptimal acoustic windows. Ongoing studies will clarify the clinical value of this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12357244\">",
"    <span class=\"h3\">",
"     CT coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of multislice CT coronary angiography (CCTA) to potentially replace invasive cardiac catheterization is an area of active investigation. CCTA is an attractive potential screening tool because it allows for direct visualization of the coronary arteries with less associated patient discomfort, risk, and cost than conventional angiography.",
"   </p>",
"   <p>",
"    A summary of study results is provided in the following table (",
"    <a class=\"graphic graphic_table graphicRef54030 \" href=\"UTD.htm?16/62/17389\">",
"     table 2",
"    </a>",
"    ). The reported sensitivity of CT angiography for CAV is limited, ranging from 59 to 88 percent in various studies. It is well documented that CT angiography is less sensitive than conventional angiography to detect distal and small vessel disease. In addition, many patients have been excluded from the studies because of poor image quality, tachycardia or renal insufficiency. While most studies have reported a high negative-predictive value, the relation of CT angio findings to long-term prognosis is unclear.",
"   </p>",
"   <p>",
"    Although multislice CT angiography is noninvasive, it adds to the burden of radiation already imposed on heart transplant recipients by repeated biopsies requiring fluoroscopy. CT angiography also requires use of significantly greater amounts of iodine containing dye than conventional angiography, thus increasing the risk of nephrotoxicity.",
"   </p>",
"   <p>",
"    At the current time, CT angiography is not recommended as a standard noninvasive tool for routine monitoring allograft vasculopathy, but future technical developments may improve image quality and reduce radiation and dye requirements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20450054\">",
"    <span class=\"h3\">",
"     Biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple biomarkers measured in peripheral blood have been evaluated as screening tools for allograft vasculopathy. Markers such as C-reactive protein (CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP), and von Willebrand factor (vWF) are each predictive of all-cause death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Although neither CRP nor NT-proBNP was predictive of CAV, patients with high levels of both had elevated risk of CAV [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/61\">",
"     61",
"    </a>",
"    ]. Elevated levels of vWF also predict CAV [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/62\">",
"     62",
"    </a>",
"    ]. Further study is needed to define the potential role of these markers for identifying CAV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12357251\">",
"    <span class=\"h2\">",
"     Endomyocardial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has long been recognized that many patients with evidence of transplant vasculopathy in the epicardial coronary arteries also have significant alterations in the microvasculature in routine endomyocardial biopsies obtained as part of allograft rejection surveillance (",
"    <a class=\"graphic graphic_picture graphicRef58790 \" href=\"UTD.htm?10/38/10855\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. The sensitivity of a histopathological diagnosis of allograft vasculopathy using angiography or IVUS as a gold standard is low, but documented microvasculopathy may have prognostic importance. In a report from a single-center study, stenosis of the coronary microvasculature was evaluated on histological examination of routine post-transplant endomyocardial biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/63\">",
"     63",
"    </a>",
"    ]. In biopsies harvested from 873 patients during the first post-transplantation year, stenotic microvasculopathy was detected in 43 percent of biopsies and was predominantly due to medial disease. Stenotic microvasculopathy was associated with reduced overall survival (10.9 versus 13.4 years) and decreased freedom from fatal cardiac events (96 versus 99 percent, 87 versus 97 percent, and 76 versus 90 percent at 1, 5, and 10 years, respectively).",
"   </p>",
"   <p>",
"    In this study, the occurrence of microvasculopathy was independent of the existence of epicardial transplant vasculopathy. However, patients with microvasculopathy detected at 271 to 365 days post-transplantation were at increased risk of later developing stenotic three-vessel epicardial disease (odds ratio 3.28). However further study is needed to define the potential prognostic value of microvasculopathy and the potential role of microvasculopathy detection in disease management has not been defined. It has been postulated that microvasculopathy may represent a sensitive marker for the risk of developing transplant vasculopathy, and thus is a potential surrogate endpoint in future prevention trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18585/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=see_link\">",
"       \"Patient information: Heart transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=see_link\">",
"       \"Patient information: Heart transplantation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12357272\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial monitoring for the detection of cardiac allograft vasculopathy (CAV) is recommended, since it limits long-term survival in cardiac transplant recipients, and because medical and interventional therapies may be effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link\">",
"     \"Prevention and treatment of cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following approach is recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine invasive coronary angiography should be performed annually in all patients (including asymptomatic ones) during the first five years after cardiac transplantation. Late after transplantation (for instance, five years), low-risk individuals (ie, those with normal coronary angiography at five years) may be followed using noninvasive techniques, preferably",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiography. (See",
"      <a class=\"local\" href=\"#H12357209\">",
"       'Coronary angiography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12357230\">",
"       'Noninvasive studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Invasive coronary angiography should be considered when there is a decrease in cardiac allograft function that is not explained by transplant rejection.",
"     </li>",
"     <li>",
"      Intravascular ultrasound or coronary flow reserve measurements should be considered when angiographic findings seem insufficient to explain left ventricular dysfunction.",
"     </li>",
"     <li>",
"      Due to the concentric nature of the stenoses associated with transplant vasculopathy, coronary angiography can severely underestimate the presence and burden of this process. Intravascular ultrasound overcomes this limitation of routine coronary angiography.",
"     </li>",
"     <li>",
"      Late post-transplant,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      &nbsp;stress echocardiography is a reasonable substitute for screening coronary angiography in low-risk individuals (ie, those with normal coronary angiography at five years), or if renal dysfunction substantially increases the risk of contrast nephropathy. An abnormal dobutamine stress echocardiogram result should prompt immediate coronary arteriography.",
"     </li>",
"     <li>",
"      Invasive coronary arteriography should be performed promptly in patients with symptoms suggestive of transplant vasculopathy, even if",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiogram or other noninvasive work-up is negative.",
"     </li>",
"     <li>",
"      CT coronary angiography is a promising technique, but at the current time sensitivity to detect significant coronary vasculopathy is too low to recommend this modality as a screening tool.",
"     </li>",
"     <li>",
"      The clinical utility of screening endomyocardial biopsy specimens for microvasculopathy has not yet been defined.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/1\">",
"      Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007. J Heart Lung Transplant 2007; 26:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/2\">",
"      Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010; 29:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/3\">",
"      Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. J Heart Lung Transplant 2009; 28:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/4\">",
"      Nagji AS, Hranjec T, Swenson BR, et al. Donor age is associated with chronic allograft vasculopathy after adult heart transplantation: implications for donor allocation. Ann Thorac Surg 2010; 90:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/5\">",
"      Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 1998; 17:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/6\">",
"      O'Neill BJ, Pflugfelder PW, Singh NR, et al. Frequency of angiographic detection and quantitative assessment of coronary arterial disease one and three years after cardiac transplantation. Am J Cardiol 1989; 63:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/7\">",
"      Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/8\">",
"      Mullins PA, Cary NR, Sharples L, et al. Coronary occlusive disease and late graft failure after cardiac transplantation. Br Heart J 1992; 68:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/9\">",
"      Gao SZ, Schroeder JS, Alderman EL, et al. Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens. Circulation 1989; 80:III100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/10\">",
"      Kofoed KF, Czernin J, Johnson J, et al. Effects of cardiac allograft vasculopathy on myocardial blood flow, vasodilatory capacity, and coronary vasomotion. Circulation 1997; 95:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/11\">",
"      John R, Rajasinghe HA, Itescu S, et al. Factors affecting long-term survival (&gt;10 years) after cardiac transplantation in the cyclosporine era. J Am Coll Cardiol 2001; 37:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/12\">",
"      Marzoa-Rivas R, Perez-Alvarez L, Paniagua-Martin MJ, et al. Sudden cardiac death of two heart transplant patients with correctly functioning implantable cardioverter defibrillators. J Heart Lung Transplant 2009; 28:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/13\">",
"      Keogh AM, Valantine HA, Hunt SA, et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant 1992; 11:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/14\">",
"      Wilson RF, McGinn AL, Johnson TH, et al. Sympathetic reinnervation after heart transplantation in human beings. J Heart Lung Transplant 1992; 11:S88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/15\">",
"      Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac-transplant recipients. Evidence of sensory reinnervation after cardiac transplantation. N Engl J Med 1991; 324:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/16\">",
"      Gao SZ, Schroeder JS, Hunt SA, et al. Acute myocardial infarction in cardiac transplant recipients. Am J Cardiol 1989; 64:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/17\">",
"      Gao SZ, Alderman EL, Schroeder JS, et al. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988; 12:334.",
"     </a>",
"    </li>",
"    <li>",
"     Wellnhofer, E, Stypmann, J, Bara, CL, et al. Angiographic assessment of cardiac allograft vasculopathy: results of a Consensus Conference of the Task Force for Thoracic Organ Transplantation of the German Cardiac Society. Transpl Int 2010; In press.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/19\">",
"      Gao SZ, Alderman EL, Schroeder JS, et al. Progressive coronary luminal narrowing after cardiac transplantation. Circulation 1990; 82:IV269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/20\">",
"      St Goar FG, Pinto FJ, Alderman EL, et al. Detection of coronary atherosclerosis in young adult hearts using intravascular ultrasound. Circulation 1992; 86:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/21\">",
"      Tuzcu EM, Kapadia SR, Sachar R, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005; 45:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/22\">",
"      Mehra MR, Ventura HO, Stapleton DD, et al. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant 1995; 14:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/23\">",
"      Fang JC, Kinlay S, Wexberg P, et al. Use of the thrombolysis in myocardial infarction frame count for the quantitative assessment of transplant-associated arteriosclerosis. Am J Cardiol 2000; 86:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/24\">",
"      Baris N, Sipahi I, Kapadia SR, et al. Coronary angiography for follow-up of heart transplant recipients: insights from TIMI frame count and TIMI myocardial perfusion grade. J Heart Lung Transplant 2007; 26:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/25\">",
"      Wolford TL, Donohue TJ, Bach RG, et al. Heterogeneity of coronary flow reserve in the examination of multiple individual allograft coronary arteries. Circulation 1999; 99:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/26\">",
"      Mazur W, Bitar JN, Young JB, et al. Progressive deterioration of coronary flow reserve after heart transplantation. Am Heart J 1998; 136:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/27\">",
"      Tuzcu EM, De Franco AC, Hobbs R, et al. Prevalence and distribution of transplant coronary artery disease: insights from intravascular ultrasound imaging. J Heart Lung Transplant 1995; 14:S202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/28\">",
"      Yeung AC, Davis SF, Hauptman PJ, et al. Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. Multicenter Intravascular Ultrasound Transplant Study Group. J Heart Lung Transplant 1995; 14:S215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/29\">",
"      Tuzcu EM, Hobbs RE, Rincon G, et al. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation. Insights from intravascular ultrasound. Circulation 1995; 91:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/30\">",
"      Rickenbacher PR, Pinto FJ, Chenzbraun A, et al. Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol 1995; 25:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/31\">",
"      Tuzcu EM, De Franco AC, Goormastic M, et al. Dichotomous pattern of coronary atherosclerosis 1 to 9 years after transplantation: insights from systematic intravascular ultrasound imaging. J Am Coll Cardiol 1996; 27:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/32\">",
"      Kapadia SR, Nissen SE, Ziada KM, et al. Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis: comparison by serial intravascular ultrasound imaging. Circulation 1998; 98:2672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/33\">",
"      Barbir M, Lazem F, Banner N, et al. The prognostic significance of non-invasive cardiac tests in heart transplant recipients. Eur Heart J 1997; 18:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/34\">",
"      Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005; 45:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/35\">",
"      Ramasubbu, K, Schoenhagen, P, Balghith, MA, et al. Repeated intravascular ultrasound imaging in cardiac transplant recipients does not accelerate transplant coronary artery disease. J Am Coll Cardiol 2003; 41:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/36\">",
"      Fang JC, Rocco T, Jarcho J, et al. Noninvasive assessment of transplant-associated arteriosclerosis. Am Heart J 1998; 135:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/37\">",
"      Akosah KO, McDaniel S, Hanrahan JS, Mohanty PK. Dobutamine stress echocardiography early after heart transplantation predicts development of allograft coronary artery disease and outcome. J Am Coll Cardiol 1998; 31:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/38\">",
"      Akosah KO, Mohanty PK, Funai JT, et al. Noninvasive detection of transplant coronary artery disease by dobutamine stress echocardiography. J Heart Lung Transplant 1994; 13:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/39\">",
"      Spes CH, Klauss V, Mudra H, et al. Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninvasive assessment of cardiac allograft vasculopathy: a comparison with coronary angiography and intravascular ultrasound. Circulation 1999; 100:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/40\">",
"      Carlsen J, Toft JC, Mortensen SA, et al. Myocardial perfusion scintigraphy as a screening method for significant coronary artery stenosis in cardiac transplant recipients. J Heart Lung Transplant 2000; 19:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/41\">",
"      Tse KK, Alavi A, Eisen HJ. Noninvasive diagnosis of cardiac transplant arteriopathy with dipyridamole thallium scintigraphy. J Nucl Med 1993; 34:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/42\">",
"      Elhendy A, Sozzi FB, van Domburg RT, et al. Accuracy of dobutamine tetrofosmin myocardial perfusion imaging for the noninvasive diagnosis of transplant coronary artery stenosis. J Heart Lung Transplant 2000; 19:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/43\">",
"      Elhendy A, van Domburg RT, Vantrimpont P, et al. Prediction of mortality in heart transplant recipients by stress technetium-99m tetrofosmin myocardial perfusion imaging. Am J Cardiol 2002; 89:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/44\">",
"      Manrique A, Bernard M, Hitzel A, et al. Diagnostic and prognostic value of myocardial perfusion gated SPECT in orthotopic heart transplant recipients. J Nucl Cardiol 2010; 17:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/45\">",
"      Allen-Auerbach M, Sch&ouml;der H, Johnson J, et al. Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients. J Heart Lung Transplant 1999; 18:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/46\">",
"      Gregory SA, Ferencik M, Achenbach S, et al. Comparison of sixty-four-slice multidetector computed tomographic coronary angiography to coronary angiography with intravascular ultrasound for the detection of transplant vasculopathy. Am J Cardiol 2006; 98:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/47\">",
"      Iyengar S, Feldman DS, Cooke GE, et al. Detection of coronary artery disease in orthotopic heart transplant recipients with 64-detector row computed tomography angiography. J Heart Lung Transplant 2006; 25:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/48\">",
"      Mastrobuoni S, Bastarrika G, Ubilla M, et al. Dual-source CT coronary angiogram in heart transplant recipients in comparison with dobutamine stress echocardiography for detection of cardiac allograft vasculopathy. Transplantation 2009; 87:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/49\">",
"      Pichler P, Loewe C, Roedler S, et al. Detection of high-grade stenoses with multislice computed tomography in heart transplant patients. J Heart Lung Transplant 2008; 27:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/50\">",
"      Romeo G, Houyel L, Angel CY, et al. Coronary stenosis detection by 16-slice computed tomography in heart transplant patients: comparison with conventional angiography and impact on clinical management. J Am Coll Cardiol 2005; 45:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/51\">",
"      Schepis T, Achenbach S, Weyand M, et al. Comparison of dual source computed tomography versus intravascular ultrasound for evaluation of coronary arteries at least one year after cardiac transplantation. Am J Cardiol 2009; 104:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/52\">",
"      Sigurdsson G, Carrascosa P, Yamani MH, et al. Detection of transplant coronary artery disease using multidetector computed tomography with adaptative multisegment reconstruction. J Am Coll Cardiol 2006; 48:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/53\">",
"      Usta E, Burgstahler C, Aebert H, et al. The challenge to detect heart transplant rejection and transplant vasculopathy non-invasively - a pilot study. J Cardiothorac Surg 2009; 4:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/54\">",
"      von Ziegler F, Leber AW, Becker A, et al. Detection of significant coronary artery stenosis with 64-slice computed tomography in heart transplant recipients: a comparative study with conventional coronary angiography. Int J Cardiovasc Imaging 2009; 25:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/55\">",
"      Tona F, Caforio AL, Montisci R, et al. Coronary flow reserve by contrast-enhanced echocardiography: a new noninvasive diagnostic tool for cardiac allograft vasculopathy. Am J Transplant 2006; 6:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/56\">",
"      Tona F, Osto E, Tarantini G, et al. Coronary flow reserve by transthoracic echocardiography predicts epicardial intimal thickening in cardiac allograft vasculopathy. Am J Transplant 2010; 10:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/57\">",
"      Yamani MH, Tuzcu EM, Starling RC, et al. Computerized scoring of histopathology for predicting coronary vasculopathy, validated by intravascular ultrasound. J Heart Lung Transplant 2002; 21:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/58\">",
"      Zakliczy��ski M, Konecka-Mr&oacute;wka D, Lekston A, et al. Microvasculopathy observed in early or late endomyocardial biopsies is not related to angiographically confirmed transplanted heart coronary vasculopathy. Transplant Proc 2009; 41:3209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/59\">",
"      Zakliczynski M, Nozynski J, Konecka-Mrowka D, et al. Vascular abnormalities and cardiomyocyte lipofuscin deposits in endomyocardial biopsy specimens of heart transplant recipients: are they related to the development of cardiac allograft vasculopathy? J Thorac Cardiovasc Surg 2009; 138:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/60\">",
"      Elhendy A, van Domburg RT, Vantrimpont P, et al. Impact of heart transplantation on the safety and feasibility of the dobutamine stress test. J Heart Lung Transplant 2001; 20:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/61\">",
"      Arora S, Gullestad L, Wergeland R, et al. Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation. Transplantation 2007; 83:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/62\">",
"      Mart&iacute;nez-Dolz L, Almenar L, Reganon E, et al. Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy. J Heart Lung Transplant 2008; 27:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18585/abstract/63\">",
"      Hiemann NE, Wellnhofer E, Knosalla C, et al. Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies. Circulation 2007; 116:1274.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3522 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18585=[""].join("\n");
var outline_f18_9_18585=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12357272\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12357152\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12357181\">",
"      DEFINITIONS AND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12357188\">",
"      PREVALENCE AND INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12357195\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12357202\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20449897\">",
"      Invasive imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12357209\">",
"      - Coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27764987\">",
"      - Additional invasive evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27764994\">",
"      TIMI frame count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27765001\">",
"      Coronary flow reserve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12357216\">",
"      Intravascular ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12357223\">",
"      - Predictive value of invasive evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12357230\">",
"      Noninvasive studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12357237\">",
"      - Dobutamine echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12357244\">",
"      - CT coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20450054\">",
"      - Biomarkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12357251\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12357272\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3522\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3522|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/19/8511\" title=\"figure 1\">",
"      CAV lesion types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/45/29395\" title=\"figure 2\">",
"      Diagram of pathologic changes with CAV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3522|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/38/10855\" title=\"picture 1\">",
"      Endomyocardial biopsy specimen with microvascular changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3522|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?7/59/8113\" title=\"movie 1\">",
"      Angiogram with CAV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?38/1/38929\" title=\"movie 2\">",
"      IVUS in patient with CAV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3522|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/14/9452\" title=\"table 1\">",
"      ISHLT cardiac allograft vasculopathy nomenclature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/62/17389\" title=\"table 2\">",
"      CT studies to detect CVT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=related_link\">",
"      Clinical use of coronary artery pressure and Doppler flow measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=related_link\">",
"      Pathogenesis of and risk factors for cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=related_link\">",
"      Patient information: Heart transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=related_link\">",
"      Patient information: Heart transplantation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=related_link\">",
"      Prevention and treatment of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=related_link\">",
"      Prognosis after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_9_18586="Treatment and prognosis of neuroblastoma";
var content_f18_9_18586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of neuroblastoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/9/18586/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18586/contributors\">",
"     Heidi V Russell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18586/contributors\">",
"     Jason M Shohet, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18586/contributors\">",
"     Jed G Nuchtern, MD, FACS, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/9/18586/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18586/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18586/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18586/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/9/18586/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/9/18586/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/9/18586/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term neuroblastoma is commonly used to refer to a spectrum of neuroblastic tumors (including neuroblastomas, ganglioneuroblastomas, and ganglioneuromas) that arise from primitive sympathetic ganglion cells.",
"   </p>",
"   <p>",
"    Neuroblastomas, which account for 97 percent of all neuroblastic tumors, are clinically heterogeneous, varying in location, histopathologic appearance, and biologic characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/1\">",
"     1",
"    </a>",
"    ]. They are most remarkable for their broad spectrum of clinical behavior, which can range from spontaneous regression, to maturation to a benign ganglioneuroma, or aggressive disease with metastatic dissemination leading to death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinical diversity correlates closely with numerous clinical and biological factors, although its molecular basis remains largely unknown. For example, most infants with disseminated disease have a favorable outcome after treatment with chemotherapy and surgery, while the majority of children over the age of 18 months who have advanced neuroblastoma die from progressive disease despite intensive multimodality therapy.",
"   </p>",
"   <p>",
"    The treatment and prognosis of neuroblastoma will be reviewed here. The epidemiology, clinical presentation, and diagnosis of neuroblastoma are presented separately, as is a discussion of neuroblastomas arising in the olfactory epithelium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14585?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of neuroblastoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/46/12008?source=see_link\">",
"     \"Olfactory neuroblastoma (esthesioneuroblastoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroblastomas are diverse in their clinical behavior. Certain factors influence the biologic behavior of these tumors and are helpful in predicting outcome; some are patient-related (eg, age at the time of diagnosis), while the majority are tumor-related (disease stage, tumor histology, molecular and cytogenetic features).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tumor stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of metastatic spread at presentation is the most important factor in determining outcome for patients with neuroblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Although regional spread to lymph nodes attached or adjacent to the primary tumor does not significantly affect outcome, distant metastatic disease (eg, bone marrow involvement) confers a much worse prognosis.",
"   </p>",
"   <p>",
"    In the past, pediatric cooperative groups used different staging systems, which made it difficult to compare treatments and outcomes. In the early 1990s, a uniform staging system, the International Neuroblastoma Staging System (INSS), was adopted (",
"    <a class=\"graphic graphic_table graphicRef73974 \" href=\"UTD.htm?36/45/37595\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/6\">",
"     6",
"    </a>",
"    ]. Tumor stage in this system is defined according to resectability and spread to lymph nodes or distant sites. Disease stage at diagnosis is to some extent influenced by age; a greater proportion of patients diagnosed after one year of age have stage 3 or 4 disease compared to those who present earlier (80 versus 41 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2009, the International Neuroblastoma Risk Group (INRG) proposed revisions to the staging system, incorporating pretreatment imaging parameters rather than findings at resection (",
"    <a class=\"graphic graphic_table graphicRef88604 \" href=\"UTD.htm?13/26/13739\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Preliminary studies of the INRG staging system (INRGSS) suggest that it may offer improved insights into which patients require intensive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/8\">",
"     8",
"    </a>",
"    ]. International cooperative groups, including the Children&rsquo;s Oncology Group, are validating and incorporating this staging system into their prospective research.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Stage 4S disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage 4S neuroblastoma is a special category that is reserved for infants below one year of age (",
"    <a class=\"graphic graphic_table graphicRef73974 \" href=\"UTD.htm?36/45/37595\">",
"     table 1",
"    </a>",
"    ). These infants have resectable primary tumors (Stage 1 or 2) and metastases that are limited to the liver, skin, and bone marrow; infants with metastases to cortical bone are excluded from this category. The INRGSS modified the definition of 4S (called Ms) to include patients up to 18 months of age and those with regional spread of primary tumor (",
"    <a class=\"graphic graphic_table graphicRef88604 \" href=\"UTD.htm?13/26/13739\">",
"     table 2",
"    </a>",
"    ). The 4S (or Ms) category is an exception to the typically dismal prognosis for children with widespread metastases from neuroblastoma. Overall survival (OS) for infants in this category is over 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/9\">",
"     9",
"    </a>",
"    ]. One contributing factor is that the tumor cells in infants with stage 4S disease have the capacity to undergo spontaneous regression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/10\">",
"     10",
"    </a>",
"    ]. However, like all stages of neuroblastomas, the tumors that make up stage 4S disease are heterogeneous, and they require heterogeneous treatment protocols (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Low-risk disease'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Age at diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age at presentation is an important prognostic factor in children with neuroblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. The significantly better outcome of disseminated disease in children under the age of one compared to other age groups is reflected in the special 4S category of disease stage, which applies only to infants. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Stage 4S disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The younger the age at diagnosis, the better the survival rate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. An age of 18 months appears to be appropriate for risk group stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/15\">",
"     15",
"    </a>",
"    ], and this age has been incorporated into the current treatment regimens as well as the proposed INRGSS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/5\">",
"     5",
"    </a>",
"    ]. Five-year survival rates for neuroblastoma derived from data of the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute are 83, 55, and 40 percent for children younger than one year, one to four years, and five to nine years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/1\">",
"     1",
"    </a>",
"    ]. Even favorable or less aggressive-appearing neuroblastomas fare worse as children get older [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathologic risk classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Newborns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates (younger than four to six weeks) who have stage 4S neuroblastoma are an exception to the general rule that younger age is associated with better outcome. Among this small subset of patients, neuroblastoma in the liver can grow rapidly, resulting in pulmonary compromise and renal failure in approximately 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/9,11,15\">",
"     9,11,15",
"    </a>",
"    ]. Such infants must be monitored closely even after treatment initiation. In contrast, newborns who have limited adrenal disease (typically diagnosed by prenatal ultrasound) have a favorable prognosis and frequently do not need treatment. (See",
"    <a class=\"local\" href=\"#H433137774\">",
"     'Infants with small adrenal masses'",
"    </a>",
"    below.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathologic risk classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, the balance between neural-type cells and Schwann-type (Schwannian) cells helps to categorize the tumor as neuroblastoma, ganglioneuroblastoma, or ganglioneuroma. In turn, neuroblastomas can have varying degrees of differentiation (undifferentiated, poorly differentiated, or differentiating). These histologic subtypes are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14585?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, pathogenesis, and pathology of neuroblastoma\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histology, in addition to age, is important prognostically. In 1984, Shimada et al derived a pathologic risk classification scheme that relates the histopathologic features of the tumor, other biologic variables, and patient age to clinical behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/19\">",
"     19",
"    </a>",
"    ]. Tumors are classified as favorable or unfavorable based upon the degree of neuroblast differentiation, Schwannian stroma content, the frequency of cell division (the mitosis-karyorrhexis index [MKI]), and age at diagnosis.",
"   </p>",
"   <p>",
"    The International Neuroblastoma Pathology Classification (INPC) system, a modification of the Shimada system, was established in 1999 and its prognostic value subsequently confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In one validation study, five-year event-free survival (EFS) was more than three times greater among children with favorable compared to unfavorable disease (90 versus 27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to this system, favorable tumors include those that are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poorly differentiated or differentiating neuroblastoma, with low or intermediate mitosis-karyorrhexis index (MKI), patient age &le;1.5 years",
"     </li>",
"     <li>",
"      Differentiating neuroblastoma and low MKI tumors in patients 1.5 to 5.0 years of age",
"     </li>",
"     <li>",
"      Ganglioneuroblastoma, intermixed, regardless of age",
"     </li>",
"     <li>",
"      Ganglioneuroma, regardless of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfavorable tumors include those that are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Undifferentiated or high MKI tumors in patients of any age",
"     </li>",
"     <li>",
"      Poorly differentiated",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intermediate MKI tumors in patients 1.5 to 5.0 years of age",
"     </li>",
"     <li>",
"      Any grade of differentiation and any MKI class in patients &ge;5 years of age",
"     </li>",
"     <li>",
"      Nodular ganglioneuroblastoma, regardless of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cytogenetics and molecular genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no pathognomonic genetic or chromosomal alteration has been identified in neuroblastomas, certain molecular and cytogenetic characteristics correlate with prognosis, including",
"    <em>",
"     MYCN",
"    </em>",
"    (",
"    <em>",
"     N-myc",
"    </em>",
"    ) amplification, DNA content (ploidy), and gain or loss of whole or partial chromosomes. The importance of",
"    <em>",
"     MYCN",
"    </em>",
"    amplifications, ploidy, and segmental chromosomal aberrations are reflected in their inclusion as prognostic factors in determining risk assignment for treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14585?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology, pathogenesis, and pathology of neuroblastoma\", section on 'Molecular pathogenesis and implications for prognosis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modern treatment of neuroblastoma is determined based on risk categories (",
"    <a class=\"graphic graphic_table graphicRef68159 \" href=\"UTD.htm?33/53/34653\">",
"     table 3",
"    </a>",
"    ). Patients are classified into low, intermediate, and high risk categories based on the following characteristics at the time of diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage of the disease",
"     </li>",
"     <li>",
"      Patient age",
"     </li>",
"     <li>",
"      Histologic appearance of the tumor",
"     </li>",
"     <li>",
"      Presence or absence of amplification of the",
"      <em>",
"       MYCN",
"      </em>",
"      oncogene",
"     </li>",
"     <li>",
"      Quantitative DNA content of the tumor (DNA index or ploidy). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk categories are expected to evolve as newer staging systems are adopted and further knowledge is acquired about molecular and genetic determinants of tumor behavior and prognosis. As an example, the current Children's Oncology Group risk categorization schema (",
"    <a class=\"graphic graphic_table graphicRef68159 \" href=\"UTD.htm?33/53/34653\">",
"     table 3",
"    </a>",
"    ) will likely undergo further modifications to incorporate the International Neuroblastoma Risk Group staging system (INRGSS) and include prognostic genetic changes such as segmental chromosomal aberrations (eg, loss of heterozygosity [LOH] 11q) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Tumor stage'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Low-risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in the low-risk category generally have low stage disease (eg, stage 1, 2A, or 2B, (",
"    <a class=\"graphic graphic_table graphicRef73974 \" href=\"UTD.htm?36/45/37595\">",
"     table 1",
"    </a>",
"    )) and tumors are",
"    <em>",
"     MYCN",
"    </em>",
"    non-amplified, hyperdiploid and have favorable histology. In general, tumor outcomes for children with low-risk neuroblastoma are excellent. Surgery is the mainstay of treatment for low risk tumors although some infants and children need additional chemotherapy and others can be observed without surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433137982\">",
"    <span class=\"h3\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectant observation is a reasonable alternative in some newborns with small adrenal masses and some infants with localized neuroblastoma or asymptomatic stage 4S disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433137774\">",
"    <span class=\"h4\">",
"     Infants with small adrenal masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns who have small adrenal masses detected by prenatal ultrasound represent a favorable cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Surgery alone is curative, although it can be associated with significant morbidity and mortality. Observational studies suggest that expectant observation is a safe alternative to surgery in newborns with localized neuroblastoma, and that many of these tumors spontaneously regress [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/26-34\">",
"     26-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a Children&rsquo;s Oncology Group prospective study of 87 infants younger than six months with small adrenal masses (diameter up to 3.1 cm for solid masses and 5.0 cm for cystic masses), 83 of whom elected observation, spontaneous reduction in tumor volume was noted in two thirds of patients, including 27 patients with no residual mass by the end of follow up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/34\">",
"     34",
"    </a>",
"    ]. Surgery was avoided in 81 percent of patients with a median follow up of 3.2 years, and 3-year overall survival was 100 percent. Among 20 patients who underwent resection, the majority had confirmed stage I disease. A diagnosis other than neuroblastoma was observed in seven patients at the time of surgery; alternative diagnoses included extralobar pulmonary sequestration, adrenal cortical neoplasm, and hematoma.",
"   </p>",
"   <p>",
"    Patients should be referred for surgery if there is evidence of progressive tumor enlargement during the period of observation. Chemotherapy is not indicated unless disease progresses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H974579\">",
"    <span class=\"h4\">",
"     Localized neuroblastoma in children less than one year",
"    </span>",
"    &nbsp;&mdash;&nbsp;A strategy of initial observation has been applied to children less than one year of age with localized, pathologically proven neuroblastoma (stage 1 or 2) without",
"    <em>",
"     MYCN",
"    </em>",
"    amplification. In a prospective, nonrandomized multicenter study, 93 of 340 children (27 percent) were observed without either primary resection of gross residual tumor or chemotherapy following the initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/35\">",
"     35",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At a median follow-up of 58 months, spontaneous remissions were observed in 44 cases (including 17 complete), while 39 had evidence of local or distant progression, and 10 had no change in tumor size.",
"     </li>",
"     <li>",
"      Surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy were used to salvage those children who had evidence of progression.",
"     </li>",
"     <li>",
"      Tumor regression was often delayed, with median times to first evidence and complete regression of 3.3 and 10 months, respectively. The first evidence of regression did not appear until after age one year in 15 of the 44 cases (34 percent).",
"     </li>",
"     <li>",
"      The three-year overall and metastasis-free survival rates for those initially managed with observation were 99 and 94 percent, not significantly different from those initially managed with surgery or chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2203460\">",
"    <span class=\"h4\">",
"     Infants with stage 4S disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high rate of spontaneous regression is seen in infants with stage 4S disease; as a result, treatment can be deferred in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. Although survival is excellent with minimal or no therapy, observation is not appropriate for all 4S patients. Subsets of patients with 4S disease and a poor prognosis include infants less than two months old, diploid tumor or undifferentiated tumor,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <em>",
"     MYCN",
"    </em>",
"    amplification [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prognostic factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In one report of 80 infants with 4S disease, none of whom had",
"    <em>",
"     MYCN",
"    </em>",
"    amplification, the five-year event-free survival (EFS) and overall survival rates were 86 and 92 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/11\">",
"     11",
"    </a>",
"    ]. All 44 infants who received supportive care alone were alive at five years, compared to 81 percent of those who required cytotoxic therapy for symptoms. Five of the six deaths were in infants younger than two months of age and were due to extensive hepatomegaly, suggesting that aggressive initial therapy should be considered in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery alone is the primary treatment for low-risk tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. Resectability is determined by tumor location and mobility, relationship to major nerves and blood vessels, the presence of distant metastases, and patient age. Sacrifice of vital organs to achieve a complete resection of large primary tumors at the time of diagnosis should be avoided, particularly in infants who have a favorable prognosis. Surgery should be delayed in circumstances when less than 50 percent of the tumor can be safely removed and neoadjuvant chemotherapy should be administered to reduce the size of the tumor prior to surgery. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Two- to five-year EFS rates with surgery alone are greater than 93 percent for children with stage 1 disease; because recurrences can be successfully managed with further surgery or chemotherapy, five-year survival rates are 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/36,37,41-43\">",
"     36,37,41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most children with stage 2A or 2B disease and no symptoms, the outlook after surgery alone is also excellent. Chemotherapy was a component of early treatment regimens but has gradually been removed over successive clinical trials without detriment to patients outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/36-38,41,42\">",
"     36-38,41,42",
"    </a>",
"    ]. This was illustrated by a Children&rsquo;s Oncology Group clinical trial for low-risk neuroblastoma that included 306 asymptomatic, stage 2A and 2B infants and children who underwent surgical resection and then close follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/43\">",
"     43",
"    </a>",
"    ]. Five-year overall survival was similar in patients with stage 2A disease compared with 2B disease (98 versus 96 percent), despite a significantly lower EFS in patients with stage 2B disease (85 versus 92 percent). Patient age and tumor characteristics such as DNA content and histology were important prognostic factors in these patients that contributed to the lower EFS in patients with stage 2B disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with low-risk disease, multi-agent low or moderate intensity chemotherapy is reserved for those whose tumors cannot be resected or who have threatening symptoms of spinal cord compression or respiratory or bowel compromise. Frequently used agents include combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4983?source=see_link\">",
"     teniposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Among patients who have localized but unresectable disease, primary chemotherapy may be used to shrink the primary tumor and resection delayed until it can be performed safely [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. The success of this approach is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 52 children with localized but unresectable neuroblastomas received two courses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      plus two cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (CAdO) followed by attempted resection [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/45\">",
"       45",
"      </a>",
"      ]. The response rate was 66 percent, and the primary tumor could be removed in all children but one; that child achieved a complete remission with chemotherapy alone.",
"     </li>",
"     <li>",
"      Another series included 28 infants with unresectable localized neuroblastoma without",
"      <em>",
"       MYCN",
"      </em>",
"      amplification or threatening local symptoms, who received one to three courses of low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for five days) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      (0.05",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on day 1) every two weeks until surgical excision could be safely performed [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/44\">",
"       44",
"      </a>",
"      ]. Fourteen responded to the low-dose regimen, while the remainder required second-line therapy (CAdO). Complete resection was possible in 23, although 10 had a \"very good partial resection\". With a median follow-up of 55 months, there were three local relapses, all salvaged by conventional dose chemotherapy and surgery.",
"     </li>",
"     <li>",
"      In a report of 47 children with primary localized pelvic neuroblastoma, 21 initially unresectable cases underwent induction chemotherapy while the remainder underwent surgery followed by chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/46\">",
"       46",
"      </a>",
"      ]. At the end of therapy, 31 (66 percent) were in complete remission, and 12 (26 percent) had a \"very good partial response\". With a median follow-up of 48 months, 44 remained alive, and six relapsed locally, four of whom achieved a second remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) is reserved for unresectable tumors or progressive tumors unresponsive to chemotherapy or for those with life threatening complications, neurologic compromise, or tumor-related organ dysfunction unresponsive to emergency chemotherapy. RT is generally avoided in all other clinical scenarios given the overall excellent survival for this patient group and the long-term complications of RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Intermediate-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the Children Oncology Group risk classification schema, intermediate-risk disease includes those children younger than 18 months of age with stage 3 disease without",
"    <em>",
"     MYCN",
"    </em>",
"    amplification (regardless of histology), and stage 3 disease in children older than 18 months without",
"    <em>",
"     MYCN",
"    </em>",
"    amplification and with favorable histologic features. In addition, this stratum also includes infants with stage 4 disease without",
"    <em>",
"     MYCN",
"    </em>",
"    amplification (",
"    <a class=\"graphic graphic_table graphicRef73974 \" href=\"UTD.htm?36/45/37595\">",
"     table 1",
"    </a>",
"    ), and a subset of infants with 4S disease who have diploid tumors or unfavorable histology, and no",
"    <em>",
"     MYCN",
"    </em>",
"    amplification (",
"    <a class=\"graphic graphic_table graphicRef68159 \" href=\"UTD.htm?33/53/34653\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The standard approach for these patients includes chemotherapy with resection when possible. Radiation therapy is rarely indicated but should be considered for those with tumor progression or tumor-related life threatening or organ-threatening complications unresponsive to chemotherapy. The duration of chemotherapy is typically 12 to 24 weeks; optimization of chemotherapy according to risk factors is a focus of current clinical investigations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For intermediate-risk neuroblastoma, surgical biopsy is necessary to obtain a diagnosis and discern histologic and genomic features, but the ultimate extent of surgical resection necessary for optimal outcomes has not yet been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Furthermore, for children with regional or widespread disease, complete resection may not be possible initially because of proximity to vital structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderately intensive multiagent chemotherapy (eg, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , a platinum drug, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ) is recommended for children with intermediate-risk neuroblastoma and is often applied before attempted resection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/14\">",
"     14",
"    </a>",
"    ]. The success of a combined-modality approach to treatment was initially illustrated in a report from the CCG, in which 143 children with intermediate-stage disease received five courses of chemotherapy over a period of 15 weeks, followed by surgery, one more course of chemotherapy, RT for gross residual disease, and 16 additional weeks of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/14\">",
"     14",
"    </a>",
"    ]. The four-year EFS and overall survival rates for patients with normal",
"    <em>",
"     MYCN",
"    </em>",
"    and favorable histology was 100 percent each, while for infants with at least one unfavorable biologic feature, they were 90 and 93 percent, respectively.",
"   </p>",
"   <p>",
"    As a result of treatment successes with this regimen, subsequent clinical investigations have decreased chemotherapy intensity and aggressiveness of local control measures, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Children&rsquo;s Oncology Group trial for intermediate risk neuroblastoma, four cycles of chemotherapy were given for tumors with favorable biologic features and eight cycles were given for tumors with unfavorable features [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/49\">",
"       49",
"      </a>",
"      ]. Children treated in this way did just as well as in previous studies, with three-year event-free and overall survival of 88 and 96 percent, respectively. Importantly, radiation was used only for emergent conditions (2.5 percent of patients received radiation therapy), and the degree of primary tumor resection did not impact survival.",
"     </li>",
"     <li>",
"      In a study performed by the Society of Pediatric Oncology European Neuroblastoma Network, infants with unresectable tumors received low doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      until tumors were resectable. This study of 180 infants included 84 children with stage 3 tumors. Again, the reduction in chemotherapy was not detrimental to five-year event-free or overall survival, which remained 90 and 99 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ongoing cooperative group treatment regimens are further reducing both the duration of treatment and the cumulative doses of cytotoxic chemotherapy agents for those children with favorable tumor features in order to minimize toxicity while maintaining a high cure rate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, cooperative groups withhold RT for patients with intermediate-risk disease, and recommend it only in the setting of disease progression despite surgery and chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/2,49\">",
"     2,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     High-risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at the highest risk for disease progression and mortality are those who are older than 18 months year of age and have disseminated disease, or localized disease with unfavorable markers such as",
"    <em>",
"     MYCN",
"    </em>",
"    amplification (",
"    <a class=\"graphic graphic_table graphicRef68159 \" href=\"UTD.htm?33/53/34653\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Historically, the long-term survival probability for children with high-risk disease was less than 15 percent. Better results have been achieved using an aggressive multimodality approach that includes chemotherapy, surgical resection, high-dose chemotherapy with hematopoietic stem-cell rescue, and radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, current survival rates remain unacceptably low (approximately 40 percent), and the improved outcome has come at a cost of significant early and late toxicity.",
"   </p>",
"   <p>",
"    The following briefly summarizes the components of modern therapy for high-risk disease; specific treatment details are beyond the scope of this review:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Induction",
"      </strong>",
"      : In the induction phase, intensive chemotherapy with a combination of agents (eg, platinum agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) is used to shrink primary and metastatic tumors;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4983?source=see_link\">",
"       teniposide",
"      </a>",
"      may be used outside of the United States.",
"     </li>",
"     <li>",
"      <strong>",
"       Local Control",
"      </strong>",
"      : Local control of the primary tumor is achieved with surgical resection and radiation therapy. &nbsp;The importance of achieving a gross total resection of the primary tumor in patients with disseminated disease is controversial, with some studies [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/14,53-57\">",
"       14,53-57",
"      </a>",
"      ] but not others [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/47,58,59\">",
"       47,58,59",
"      </a>",
"      ] suggesting a better outcome for complete resection. Surgical resection of the tumor should be performed by a pediatric surgeon with experience in resecting extensive, infiltrating tumors. Resection may be performed after several courses of induction chemotherapy, when the tumor is smaller and less invasive. Radiotherapy dosed to the primary tumor bed and other sites of bulky disease may be beneficial in preventing local tumor recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. Whether completeness of resection impacts outcome is likely related to the concurrent use and dosage of radiotherapy delivered to the primary tumor bed [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Consolidation",
"      </strong>",
"      : After tumor bulk has been decreased by chemotherapy and surgery, the consolidation phase includes higher-dose chemotherapy followed by autologous hematopoietic stem cell rescue [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. The fact that the majority of high-risk patients have bone marrow metastases at the time of diagnosis would appear to compromise the use of autologous marrow for reconstitution, and early clinical trials utilized immunomagnetic &ldquo;purging&rdquo; of stem cell products [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/51\">",
"       51",
"      </a>",
"      ]. However, anti-tumor purging of peripheral blood stem cell products using an immunomagnetic approach did not decrease the risk of recurrence or improve overall survival in a prospective, randomized trial performed by the Children's Oncology Group [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Maintenance",
"      </strong>",
"      : The final phase of therapy is geared toward eradication of minimal residual disease. &nbsp; Biologic differentiation therapy with cis-retinoic acid is the backbone of maintenance therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/51\">",
"       51",
"      </a>",
"      ]. Additional immunotherapy with anti-GD2 antibodies and cytokines (granulocyte macrophage colony stimulating factor and interleukin 2) was also found to have benefit over cis-retinoic acid alone for prevention of recurrence in a randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/63\">",
"       63",
"      </a>",
"      ]: The immunotherapy approach resulted in a statistically significant improvement in the two-year event-free and overall survival rates (66 versus 46 percent, and 86 versus 75 percent, respectively). This therapy remains available through a non-randomized Children&rsquo;s Oncology Group clinical trial pending approval by the US Food and Drug Administration while the role of interleukin 2 is being studied in an ongoing European trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1337816\">",
"    <span class=\"h3\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite intensive multimodality therapy, only approximately 40 percent of children remain disease-free long-term, and the most common outcome of high-risk neuroblastoma is recurrence of disease followed by death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/2\">",
"     2",
"    </a>",
"    ]. Improving survival in this group of children is a priority in international cooperative groups.",
"   </p>",
"   <p>",
"    Maximizing the intensity of therapy with stem cell rescue and identifying the best chemotherapy combinations are two directions of research. Pilot studies of even more intensive therapy over a longer duration of time, such as tandem transplants (ie, more than one course of high-dose therapy with autologous stem cell rescue in rapid succession) show some promise, with reports suggesting survival rates of over 50 percent at up to seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/64-67\">",
"     64-67",
"    </a>",
"    ]. Studies comparing single and tandem transplant are forthcoming. The best chemotherapy combination for high dose therapy is also under study, with preliminary results of one randomized study suggesting an advantage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    over melphalan plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Novel therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of new methods to treat high-risk neuroblastoma is an active area of research in pediatric oncology. A full description of possible approaches is beyond the scope of this review. In general, novel treatments are given within a clinical trial because risks of such treatment are not fully known. Examples of therapies under investigation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunotherapies such as anti-GD2 antibodies modified to decrease toxicities [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/69\">",
"       69",
"      </a>",
"      ], targeted autologous T-cells [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/70,71\">",
"       70,71",
"      </a>",
"      ], and neuroblastoma vaccines [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Targeted therapy with drugs that act through known genetic mutations (eg, ALK [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/74\">",
"       74",
"      </a>",
"      ]) or induce apoptosis (eg, fenretinide [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/75\">",
"       75",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Modifiers of the tumor microenvironment such as antiangiogenic agents or bisphosphonates [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/76\">",
"       76",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link\">",
"       \"Overview of angiogenesis inhibitors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Iodine-131-metaiodobenzylguanidine (MIBG), in conjunction with autologous peripheral blood stem cell rescue [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/77\">",
"       77",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433139908\">",
"    <span class=\"h1\">",
"     MEDICAL COMPLICATIONS ASSOCIATED WITH NEUROBLASTOMA PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1339499\">",
"    <span class=\"h2\">",
"     Tumor lysis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bulky or advanced stage disease may be classified as being at intermediate risk for tumor lysis syndrome and prophylaxis against the complications of tumor lysis syndrome may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Spinal cord compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 7 and 15 percent of children with neuroblastoma present with spinal cord involvement. Spinal cord compression is considered an oncologic emergency. Prompt resolution is important to limit permanent neurologic impairment. Neurologic recovery appears to be related to the severity of presenting neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. In one study of 83 children with intraspinal neuroblastoma, 43 had neurologic symptoms at the time of diagnosis; complete neurologic function was recovered among 17 of 22 patients with mild symptoms (paresis alone), two of five patients with moderate deficits (paresis and",
"    <span class=\"nowrap\">",
"     bowel/bladder",
"    </span>",
"    dysfunction), and 6 of 15 severely affected patients (paralysis); one patient with mild symptoms could not be assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/79\">",
"     79",
"    </a>",
"    ]. In a review of 99 children with spinal cord involvement, 71 had residual impairments after a median follow-up of eight years. The most common impairments in this population were motor function, scoliosis, and bladder function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy and laminectomy have equivalent overall survival outcomes. Each therapeutic modality, however, carries inherent long-term and short term risks and should be determined on an individualized basis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/79,82\">",
"     79,82",
"    </a>",
"    ]. RT is generally reserved for progressive symptoms despite chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Opsoclonus myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroblastomas associated with the paraneoplastic opsoclonus-myoclonus-ataxia (OMA) syndrome are usually of lower stage and have favorable prognosis for survival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. However, children who have OMA are often left with long-term neurologic deficits (eg, cognitive and motor delays, language deficits, and behavioral abnormalities) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/83,85-88\">",
"     83,85-88",
"    </a>",
"    ]. For example, in the largest of these studies of outcome in children with neuroblastoma and OMA, 20 of 29 children had persistent neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/83\">",
"     83",
"    </a>",
"    ]. Chemotherapy, corticosteroids, and IV immune globulin may improve long-term neurologic outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/83,88,89\">",
"     83,88,89",
"    </a>",
"    ]. Symptoms refractory to these treatments may respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\", section on 'Paraneoplastic syndromes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42023?source=see_link\">",
"     \"Opsoclonus myoclonus ataxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome for patients with neuroblastoma depends upon both tumor and patient characteristics, including stage, histology,",
"    <em>",
"     MYCN",
"    </em>",
"    amplification, DNA ploidy, age at diagnosis, and extent and site of metastases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants less than one year of age have a better survival rate than older children (five-year survival rate of 83 percent, 55 percent, and 40 percent for those younger than one year, one to four years, and five to nine years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/1\">",
"       1",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      For patients with low-risk tumors (stage 1 or 2 disease, infants with stage 4S disease and favorable biologic factors), surgery alone is the primary treatment. Two-year event-free survival rates are between 85 and 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/47,92,93\">",
"       47,92,93",
"      </a>",
"      ]. Patients who relapse generally can be salvaged with further surgery or chemotherapy.",
"     </li>",
"     <li>",
"      Some infants with asymptomatic localized neuroblastoma or asymptomatic stage 4S disease without hepatomegaly and newborns with prenatally diagnosed limited adrenal disease may not require immediate therapy and may be observed for evidence of progression.",
"     </li>",
"     <li>",
"      Among patients with stage 3 neuroblastoma (intermediate- or high-risk, depending upon other prognostic factors), outcome varies according to age at diagnosis and histologic features. In one study, four-year event-free survival was 93 percent for infants, but only 54 percent for patients older than two years of age with unfavorable biologic features [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The treatment of patients with intermediate-risk neuroblastoma requires the addition of moderate-dose intensity chemotherapy to surgery, with local RT having a limited role. Long-term survival rates are over 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with high-risk disease (older than 18 months of age with disseminated disease at diagnosis, or disseminated or localized disease with unfavorable biologic and histologic markers such as",
"      <em>",
"       MYCN",
"      </em>",
"      amplification) do poorly even with intensive multimodality strategies that include high-dose therapy with autologous hematopoietic stem cell rescue. Long-term survival rates are approximately 40 percent. These patients should be encouraged to enroll in treatment protocols evaluating new therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Long-term effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimated one of every 900 people between 15 and 45 years of age in the United States is a survivor of childhood cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/87\">",
"     87",
"    </a>",
"    ]. Both the specific malignancy and its treatment can have significant long-term medical, cognitive, and",
"    <span class=\"nowrap\">",
"     social/emotional",
"    </span>",
"    effects on these survivors.",
"   </p>",
"   <p>",
"    Examples of the mechanisms by which the disease or its treatment may affect survivors include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular injury at the time of tumor resection may cause ischemic damage to the kidney. Renal atrophy may also occur following radiation therapy to the adrenal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abdominal primary tumor beds.",
"     </li>",
"     <li>",
"      Multiple endocrine effects are possible, including impaired linear growth, thyroid dysfunction, and infertility [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/94,95\">",
"       94,95",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7286?source=see_link\">",
"       \"Endocrine surveillance in childhood cancer survivors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Secondary malignancies, particularly myelodysplasia and leukemia, are well described after therapy for high-risk neuroblastoma [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/96,97\">",
"       96,97",
"      </a>",
"      ]. Patients who received chemotherapy should be followed with complete blood counts, including bone marrow studies if abnormalities arise. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"       \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laminectomy, which may be required in the treatment of intraspinal tumor, increases the risk of scoliosis because of asymmetric growth of vertebral bodies [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/79,98,99\">",
"       79,98,99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies of childhood cancer survivors indicate that cognitive deficits are more common among those who received cranial irradiation prior to five years of age. Because brain metastases are uncommon in neuroblastoma, cranial irradiation is rarely used. Total-body irradiation (TBI) has been included in some transplant protocols. In one follow-up study of 16 children whose neuroblastoma treatment included TBI, no neuropsychological complications were noted [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/100\">",
"       100",
"      </a>",
"      ]. Because of these known late effects, TBI has been eliminated from most current transplant regimens. Children who receive chemotherapy or TBI should undergo formal neurocognitive evaluation after completion of therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"       \"Complications of cranial irradiation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, some extrapolation can be made from the literature about treatment modalities that are widely used in childhood malignancies and are not exclusive to neuroblastoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anthracyclines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ) cause myocardial dysfunction and impaired myocardial growth [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/101,102\">",
"       101,102",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Platinum drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      are associated with ototoxicity, neurotoxicity, and nephrotoxicity. Renal function by creatinine clearance or glomerular filtration rate should be evaluated at the end of therapy; if abnormalities are present the patient should be followed as clinically indicated. Other measures of renal function such as serum creatinine, sodium levels, and blood pressure should be followed annually. Hearing loss is a common complication of treatment for high-risk neuroblastoma and occurs in 25 to 82 percent of patients who have undergone high-dose chemotherapy with stem-cell rescue [",
"      <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/103-105\">",
"       103-105",
"      </a>",
"      ]. A full evaluation of hearing should be performed at the end of therapy; if abnormalities are present, the patient should be followed as clinically indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link\">",
"       \"Cisplatin nephrotoxicity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"       \"Evaluation of hearing impairment in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of the disease and its treatment on survivor well-being is illustrated by a series of 954 neuroblastoma patients from the Childhood Cancer Survivor Study diagnosed between 1970 and 1986 who survived for at least five years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/9/18586/abstract/106\">",
"     106",
"    </a>",
"    ]. This group was compared with the general population for overall mortality and with a cohort of 3899 siblings for the incidence of chronic illnesses and psychosocial outcomes.",
"   </p>",
"   <p>",
"    Key findings included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a significant increase in mortality (standardized mortality ratio 5.6, 95% CI 4.4-6.9). The primary causes of increased mortality were recurrent disease and second malignancies.",
"     </li>",
"     <li>",
"      Chronic health conditions were significantly increased, with a 20-year cumulative incidence of 41 percent (relative risk 8.3, 95% CI 7.1-9.7). These chronic health conditions most commonly involved the neurologic, sensory, endocrine, and musculoskeletal systems (30, 9, 8, and 8 percent, respectively, at 20 years).",
"     </li>",
"     <li>",
"      Psychosocial factors were also adversely affected. As an example, neuroblastoma survivors were significantly less likely to have ever married or to have never been employed (55 versus 68 percent and 1.3 versus 0.2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neuroblastoma survivors should be followed by a pediatric oncologist whenever possible. The frequency of follow-up varies depending upon the type of treatment received. Initially all children are followed every few months for recurrence of disease and organ toxicity, but over the first few years, this spreads out to annual visits.",
"   </p>",
"   <p>",
"    Specific long-term follow-up guidelines after treatment of childhood cancer have been published by the Children's Oncology Group and are available at",
"    <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"     www.survivorshipguidelines.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroblastomas are clinically heterogeneous tumors, varying in location, histopathologic appearance, and biologic characteristics. Neuroblastomas are remarkable for their highly variable natural history, which can range from spontaneous regression, to maturation to a benign ganglioneuroma, or aggressive disease with metastatic dissemination leading to death.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvements in outcome for children with neuroblastoma have been the result of cooperative group, multicenter clinical trials, which have integrated combined modality approaches with an understanding of the prognostic factors affecting outcome. Patients should be managed in a setting where appropriate expertise in the treatment of neuroblastoma is available.",
"     </li>",
"     <li>",
"      Key factors influencing the clinical behavior of neuroblastomas include tumor stage, age at diagnosis, pathologic risk classification, cytogenetics, and molecular genetics. These factors have been combined to define low-, intermediate-, and high-risk groups, which are used to define treatment strategies (",
"      <a class=\"graphic graphic_table graphicRef68159 \" href=\"UTD.htm?33/53/34653\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef73974 \" href=\"UTD.htm?36/45/37595\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognostic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with low-risk disease, surgery is the primary treatment modality when complete resection is feasible, with several exceptions. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Low-risk disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with low-risk tumors that cannot be completely resected or which have life-threatening complications, chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy may be required.",
"     </li>",
"     <li>",
"      In the subset of patients with asymptomatic 4S disease, observation may be an option, since there is a high rate of spontaneous regression.",
"     </li>",
"     <li>",
"      For infants younger than six months of age with small, localized adrenal masses, we recommend expectant observation with serial ultrasound and urine catecholamines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with intermediate-risk disease, a combined modality approach that includes chemotherapy and surgical resection is standard. The degree of surgical resection required is under investigation. The role of radiation therapy is less clear, except in the context of disease progression despite chemotherapy plus surgery or for complications such as spinal cord compression. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Intermediate-risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with high-risk neuroblastoma, substantial improvements in long-term outcomes have been seen with aggressive combined modality approaches. These generally include chemotherapy, surgical resection, high dose chemotherapy with stem cell rescue, radiation therapy and",
"      <span class=\"nowrap\">",
"       biologic/immunologic",
"      </span>",
"      therapy. This approach has improved long-term outcomes, but the majority of patients eventually relapse and die of their disease. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'High-risk disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who have been treated for neuroblastoma are at risk for recurrence and for late complications of their treatment. Treating physicians should be aware of these potential issues. Long-term follow-up guidelines have been published by the Children's Oncology Group (available online at",
"      <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"       www.survivorshipguidelines.org",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Long-term effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995, Ries, LA, Smith, MA, Gurney, JG, et al (Eds), National Cancer Institute, Bethesda, MD 1999. p.35.",
"    </li>",
"    <li>",
"     Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma. In: Principles and Practice of Pediatric Oncology, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.886.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/3\">",
"      Castleberry RP, Shuster JJ, Smith EI. The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group. J Clin Oncol 1994; 12:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/4\">",
"      Haase GM, Atkinson JB, Stram DO, et al. Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg 1995; 30:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/5\">",
"      Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/6\">",
"      Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/7\">",
"      Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/8\">",
"      Woods WG, LaQuaglia MP. The drama of the gifted disease. J Clin Oncol 2009; 27:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/9\">",
"      Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. J Clin Oncol 1998; 16:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/10\">",
"      D'Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971; 1:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/11\">",
"      Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 2000; 18:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/12\">",
"      Evans AE, D'Angio GJ, Propert K, et al. Prognostic factor in neuroblastoma. Cancer 1987; 59:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/13\">",
"      DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999; 21:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/14\">",
"      Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 1998; 16:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/15\">",
"      London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005; 23:6459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/16\">",
"      Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005; 23:6474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/17\">",
"      George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005; 23:6466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/18\">",
"      Gaspar N, Hartmann O, Munzer C, et al. Neuroblastoma in adolescents. Cancer 2003; 98:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/19\">",
"      Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/20\">",
"      Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/21\">",
"      Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001; 92:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/22\">",
"      Navarro S, Amann G, Beiske K, et al. Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol. J Clin Oncol 2006; 24:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/23\">",
"      Attiyeh EF, London WB, Moss&eacute; YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/24\">",
"      Ho PT, Estroff JA, Kozakewich H, et al. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. Pediatrics 1993; 92:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/25\">",
"      Saylors RL 3rd, Cohn SL, Morgan ER, Brodeur GM. Prenatal detection of neuroblastoma by fetal ultrasonography. Am J Pediatr Hematol Oncol 1994; 16:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/26\">",
"      Acharya S, Jayabose S, Kogan SJ, et al. Prenatally diagnosed neuroblastoma. Cancer 1997; 80:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/27\">",
"      Yamamoto K, Hanada R, Kikuchi A, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 1998; 16:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/28\">",
"      Holgersen LO, Subramanian S, Kirpekar M, et al. Spontaneous resolution of antenatally diagnosed adrenal masses. J Pediatr Surg 1996; 31:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/29\">",
"      Sauvat F, Sarnacki S, Brisse H, et al. Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer 2002; 94:2474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/30\">",
"      Nishihira H, Toyoda Y, Tanaka Y, et al. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution. J Clin Oncol 2000; 18:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/31\">",
"      Yoneda A, Oue T, Imura K, et al. Observation of untreated patients with neuroblastoma detected by mass screening: a \"wait and see\" pilot study. Med Pediatr Oncol 2001; 36:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/32\">",
"      Oue T, Inoue M, Yoneda A, et al. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study. J Pediatr Surg 2005; 40:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/33\">",
"      Tanaka M, Kigasawa H, Kato K, et al. A prospective study of a long-term follow-up of an observation program for neuroblastoma detected by mass screening. Pediatr Blood Cancer 2010; 54:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/34\">",
"      Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg 2012; 256:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/35\">",
"      Hero B, Simon T, Spitz R, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008; 26:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/36\">",
"      Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 2000; 18:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/37\">",
"      Alvarado CS, London WB, Look AT, et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2000; 22:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/38\">",
"      Rubie, H, Hartmann, O, Michon, J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Soci&eacute;t&eacute; Francaise d'Oncologie P&eacute;diatrique. J Clin Oncol 1997; 15:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/39\">",
"      Bowman LC, Castleberry RP, Cantor A, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997; 89:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/40\">",
"      De Bernardi B, Mosseri V, Rubie H, et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer 2008; 99:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/41\">",
"      Kushner BH, Cheung NK, LaQuaglia MP, et al. International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. J Clin Oncol 1996; 14:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/42\">",
"      Evans AE, Silber JH, Shpilsky A, D'Angio GJ. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol 1996; 14:2504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/43\">",
"      Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol 2012; 30:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/44\">",
"      Rubie H, Coze C, Plantaz D, et al. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy. Br J Cancer 2003; 89:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/45\">",
"      Rubie H, Plantaz D, Coze C, et al. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique. Med Pediatr Oncol 2001; 36:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/46\">",
"      Leclair MD, Hartmann O, Heloury Y, et al. Localized pelvic neuroblastoma: excellent survival and low morbidity with tailored therapy--the 10-year experience of the French Society of Pediatric Oncology. J Clin Oncol 2004; 22:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/47\">",
"      Strother D, van Hoff J, Rao PV, et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer 1997; 33:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/48\">",
"      Strother D, Shuster JJ, McWilliams N, et al. Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol 1995; 17:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/49\">",
"      Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010; 363:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/50\">",
"      Rubie H, De Bernardi B, Gerrard M, et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol 2011; 29:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/51\">",
"      Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/52\">",
"      Laprie A, Michon J, Hartmann O, et al. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification. Cancer 2004; 101:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/53\">",
"      La Quaglia MP, Kushner BH, Heller G, et al. Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg 1994; 29:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/54\">",
"      Haase GM, O'Leary MC, Ramsay NK, et al. Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg 1991; 26:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/55\">",
"      Chamberlain RS, Quinones R, Dinndorf P, et al. Complete surgical resection combined with aggressive adjuvant chemotherapy and bone marrow transplantation prolongs survival in children with advanced neuroblastoma. Ann Surg Oncol 1995; 2:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/56\">",
"      McGregor LM, Rao BN, Davidoff AM, et al. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital Experience. Cancer 2005; 104:2837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/57\">",
"      Zwaveling S, Tytgat GA, van der Zee DC, et al. Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may &gt;95 % tumour resection suffice? Pediatr Surg Int 2012; 28:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/58\">",
"      Kiely EM. The surgical challenge of neuroblastoma. J Pediatr Surg 1994; 29:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/59\">",
"      Simon T, H&auml;berle B, Hero B, et al. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol 2013; 31:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/60\">",
"      Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys 2003; 56:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/61\">",
"      Marcus KJ, Shamberger R, Litman H, et al. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol 2003; 25:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/62\">",
"      Kreissman, SG, Villablanca, JG, Seeger, RC, et al. A randomized phase III trial of myeolablative autologous peripheral blood stem cell transplant for high-risk neuroblastoma employing immunomagnetic purged versus unpurged PBSC: A Children's Oncology Group study (abstract #10011). J Clin Oncol 2008; 26:541s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/63\">",
"      Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/64\">",
"      Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000; 18:2567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/65\">",
"      Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 2002; 20:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/66\">",
"      von Allmen D, Grupp S, Diller L, et al. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant. J Pediatr Surg 2005; 40:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/67\">",
"      George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006; 24:2891.",
"     </a>",
"    </li>",
"    <li>",
"     Ladenstein RL, Poetschger U, Luksch R, et al. Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial (Abst# 2). J Clin Oncol 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/69\">",
"      Shusterman S, London WB, Gillies SD, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 2010; 28:4969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/70\">",
"      Grupp SA, Prak EL, Boyer J, et al. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin Cancer Res 2012; 18:6732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/71\">",
"      Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118:6050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/72\">",
"      Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003; 101:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/73\">",
"      Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 1998; 92:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/74\">",
"      La Madrid AM, Campbell N, Smith S, et al. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol 2012; 7:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/75\">",
"      Lovat PE, Di Sano F, Corazzari M, et al. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J Natl Cancer Inst 2004; 96:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/76\">",
"      Russell HV, Groshen SG, Ara T, et al. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer 2011; 57:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/77\">",
"      Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007; 25:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/78\">",
"      Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/79\">",
"      Katzenstein HM, Kent PM, London WB, Cohn SL. Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol 2001; 19:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/80\">",
"      Pianca C, Pistamiglio P, Veneselli E, et al. Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol 2001; 19:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/81\">",
"      Simon T, Niemann CA, Hero B, et al. Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Dev Med Child Neurol 2012; 54:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/82\">",
"      Plantaz D, Rubie H, Michon J, et al. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients--results of the NBL 90 Study of the French Society of Pediatric Oncology. Cancer 1996; 78:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/83\">",
"      Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997; 28:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/84\">",
"      De Grandis E, Parodi S, Conte M, et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics 2009; 40:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/85\">",
"      Telander RL, Smithson WA, Groover RV. Clinical outcome in children with acute cerebellar encephalopathy and neuroblastoma. J Pediatr Surg 1989; 24:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/86\">",
"      Koh PS, Raffensperger JG, Berry S, et al. Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr 1994; 125:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/87\">",
"      Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol 2002; 38:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/88\">",
"      Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001; 36:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/89\">",
"      Petruzzi MJ, de Alarcon PA. Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. J Pediatr 1995; 127:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/90\">",
"      Battaglia T, De Grandis E, Mirabelli-Badenier M, et al. Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments. Eur J Paediatr Neurol 2012; 16:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/91\">",
"      Pranzatelli MR, Tate ED, Verhulst SJ, et al. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2010; 32:e167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/92\">",
"      Kushner BH, Cheung NK, LaQuaglia MP, et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 1996; 14:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/93\">",
"      Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. J Clin Oncol 1988; 6:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/94\">",
"      van Santen HM, de Kraker J, van Eck BL, et al. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 2002; 94:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/95\">",
"      van Santen HM, de Kraker J, Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 2005; 41:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/96\">",
"      Kushner BH, Cheung NK, Kramer K, et al. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 1998; 16:3880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/97\">",
"      Rubino C, Adjadj E, Gu&eacute;rin S, et al. Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer 2003; 107:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/98\">",
"      Hoover M, Bowman LC, Crawford SE, et al. Long-term outcome of patients with intraspinal neuroblastoma. Med Pediatr Oncol 1999; 32:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/99\">",
"      Paulino AC, Fowler BZ. Risk factors for scoliosis in children with neuroblastoma. Int J Radiat Oncol Biol Phys 2005; 61:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/100\">",
"      Carpentieri, SC, Diller, L. Neuropsychological and psychosocial resiliency in children treated for neuroblastoma. Adv Neuroblastoma Res 2002; Conference 2 AD:PC-53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/101\">",
"      Bossi G, Lanzarini L, Laudisa ML, et al. Echocardiographic evaluation of patients cured of childhood cancer: a single center study of 117 subjects who received anthracyclines. Med Pediatr Oncol 2001; 36:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/102\">",
"      Johnson GL, Moffett CB, Geil JD, et al. Late echocardiographic findings following childhood chemotherapy with normal serial cardiac monitoring. J Pediatr Hematol Oncol 1996; 18:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/103\">",
"      Parsons SK, Neault MW, Lehmann LE, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 1998; 22:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/104\">",
"      Simon T, Hero B, Dupuis W, et al. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr 2002; 214:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/105\">",
"      Berg AL, Spitzer JB, Garvin JH Jr. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope 1999; 109:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/9/18586/abstract/106\">",
"      Laverdi&egrave;re C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101:1131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5203 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18586=[""].join("\n");
var outline_f18_9_18586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tumor stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Stage 4S disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Age at diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Newborns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathologic risk classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cytogenetics and molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Low-risk disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H433137982\">",
"      - Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H433137774\">",
"      Infants with small adrenal masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H974579\">",
"      Localized neuroblastoma in children less than one year",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2203460\">",
"      Infants with stage 4S disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Intermediate-risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      High-risk disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1337816\">",
"      - Other approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Novel therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H433139908\">",
"      MEDICAL COMPLICATIONS ASSOCIATED WITH NEUROBLASTOMA PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1339499\">",
"      Tumor lysis syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Spinal cord compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Opsoclonus myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Long-term effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5203\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5203|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/45/37595\" title=\"table 1\">",
"      International neuroblastoma staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/26/13739\" title=\"table 2\">",
"      International Neuroblastoma Risk Group staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/53/34653\" title=\"table 3\">",
"      COG risk strata neuroblast",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7286?source=related_link\">",
"      Endocrine surveillance in childhood cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14585?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/46/12008?source=related_link\">",
"      Olfactory neuroblastoma (esthesioneuroblastoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42023?source=related_link\">",
"      Opsoclonus myoclonus ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_9_18587="Differential dx of osmolal gap";
var content_f18_9_18587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of an elevated plasma osmolal gap",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       With anion gap metabolic acidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ethylene glycol ingestion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Methanol ingestion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       End-stage chronic kidney disease (GFR &lt;10 mL/min) without regular dialysis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetic ketoacidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcoholic ketoacidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lactic acidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Formaldehyde ingestion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paraldehyde ingestion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Without metabolic acidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ethanol or isopropyl alcohol ingestion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diethyl ether ingestion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infusion of nonconductive glycine, sorbitol, or mannitol solutions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe hyperproteinemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe hyperlipidemia",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18587=[""].join("\n");
var outline_f18_9_18587=null;
var title_f18_9_18588="Treatment of HAT";
var content_f18_9_18588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of African trypanosomiasis in adults and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        T. b. gambiense",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        T. b. rhodesiense",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Early infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Preferred",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pentamidine",
"       </td>",
"       <td>",
"        4 mg/kg/day IM or IV (over&nbsp;two hours) for&nbsp;seven days",
"       </td>",
"       <td>",
"        Suramin",
"       </td>",
"       <td>",
"        100 to 200 mg (test dose) IV, then 20 mg/kg (max 1 g) IV on days 1, 3, 7, 14, and 21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Alternative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suramin",
"       </td>",
"       <td>",
"        100 to 200 mg (test dose) IV, then 20 mg/kg (max 1 g) IV on days 1, 3, 7, 14, and 21",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Late infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Preferred",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Eflornithine",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        Nifurtimox",
"       </td>",
"       <td>",
"        <p>",
"         200 mg/kg every 12 hours IV (over&nbsp;one hour) for&nbsp;seven days",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        5 mg/kg orally every 8 hours for 10 days",
"       </td>",
"       <td>",
"        Melarsoprol*",
"       </td>",
"       <td>",
"        2.2 mg/kg/day IV for 10 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eflornithine",
"       </td>",
"       <td>",
"        100 mg/kg IV every 6 hours for 14 days",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Alternative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Melarsoprol*",
"       </td>",
"       <td>",
"        2.2 mg/kg/day IV for 10 days",
"       </td>",
"       <td>",
"        Melarsoprol*",
"       </td>",
"       <td>",
"        Three series of 3.6 mg/kg/day IV&nbsp;for three&nbsp;days spaced by intervals of&nbsp;seven days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Melarsoprol should be coadministered with prednisolone 1 mg/kg per day (up to 40 mg/kg per day), beginning one to two days before therapy and continued until therapy is completed.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18588=[""].join("\n");
var outline_f18_9_18588=null;
var title_f18_9_18589="Rx of hepatic encephalopathy";
var content_f18_9_18589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Efficacy of treatments of hepatic encephalopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Rationale",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Controlled studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        vs lactulose",
"       </td>",
"       <td class=\"subtitle2\">",
"        vs placebo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Ammonia hypothesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Decrease in ammoniagenic substrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Enemas with lactulose",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Restriction of dietary protein intake",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Inhibition of ammonia production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        Antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Neomycin, paromomycin, metronidazole",
"       </td>",
"       <td class=\"sublist_other\">",
"        =",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Rifaximin",
"       </td>",
"       <td class=\"sublist_other\">",
"        =",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Vancomycin",
"       </td>",
"       <td class=\"sublist_other\">",
"        =/+",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        Disaccharides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Lactulose",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Lactitol",
"       </td>",
"       <td class=\"sublist_other\">",
"        =",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Lactose in lactase deficiency",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        Modification of colonic flora",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Lactobacillus SF 68",
"       </td>",
"       <td class=\"sublist_other\">",
"        =",
"       </td>",
"       <td class=\"sublist_other\">",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Correction of hypokalemia",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Metabolic ammonia removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Ornithine-aspartate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Benzoate",
"       </td>",
"       <td>",
"        =",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        False neurotransmitter hypothesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Branched chain amino acid supplementation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Modified amino acid solutions (FO80 type)",
"       </td>",
"       <td>",
"        =",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        \"COMA\" solutions",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Dietary BCAA supplementation",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Increased dopamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        L-DOPA, bromocriptine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        GABA hypothesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flumazenil",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zinc",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: superior to control; =: equal to lactulose; -: no effect; &plusmn;: conflicting results; ND: not done.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18589=[""].join("\n");
var outline_f18_9_18589=null;
var title_f18_9_18590="Cavity eval device";
var content_f18_9_18590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cavity evaluation device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hologic.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18590=[""].join("\n");
var outline_f18_9_18590=null;
var title_f18_9_18591="Time to sustained disability in MS";
var content_f18_9_18591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Time to sustained disability (use of a cane) with multiple sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 476px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan&ndash;Meier survival curve of time to use of a cane (sustained Expanded Disability Status Scale score 6) from birth by age at onset of multiple sclerosis (n = 2319)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006; 66:172. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_9_18591=[""].join("\n");
var outline_f18_9_18591=null;
